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ABSTRACT
The Prostate, Lung, Colorectal, and Ovarian (PLCO) Cancer Screening Trial
(Stanford et al., 1999) was conducted in the 1990s to evaluate the screening effect
of prostate-specific antigen (PSA) tests on prostate cancer. While PSA tests led to
increased incidence of cancer diagnosis, their effect on prostate cancer mortality is
disputed. Treatment for prostate cancer is confounded by indication provided by the
cancer diagnosis that can occur earlier with PSA screening.
The null hypothesis of no benefit of screening implies unchanged prostate cancer
mortality despite a profound effect of screening on the timing of treatment occurring
at diagnosis. The difficulty in designing models to test the null hypothesis lies in
the general positive dependence induced by diagnosis always preceding cancer death.
Traditional models incorporating this dependence usually let an effect on the interme-
diate event (diagnosis) propagate through the dependence structure to the terminal
event (death), thus excluding the null hypothesis.
This work focuses on developing semiparametric joint models incorporating the
null hypothesis. Chapter II proposes a parametric conditional model for cancer inci-
dence given death. We use nonparametric maximum likelihood to develop estimators
and establish inference procedures and large sample properties. We conduct simula-
tion studies to illustrate the finite-sample properties of the method; its use in practice
is demonstrated with the analysis of the PLCO prostate cancer data, combined with
the uncontaminated controls simulated using SEER data before PSA.
In Chapter III, we extend the proposed parametric conditional model of Chap-
ter II to a semiparametric model based on a multinomial logit model for the incident
ix
event. To overcome the computational difficulty from the complexity of a multino-
mial likelihood function, an artificial latent variable is introduced to transform the
multinomial likelihood to Poisson-type, and an EM algorithm, treating the artificial
variable as missing data, is derived to obtain the nonparametric maximum likelihood
estimators. To illustrate our method, we study its performance in simulations and
apply it to the prostate cancer data.
In Chapter IV, we explore a mechanistic joint model to study the problem and
develop a test for the causal effect of screening. Applying the concept of modulation
that describes how the occurrence of a latent event affects the risk of a future event in
a time-dependent fashion, the proposed model belongs to a class of stochastic process
frailty models. The profile likelihood-based method is considered for inference. We
study efficiency gains of joint modeling recognizing a common cancer progression
process driving incidence and mortality. The method is illustrated with simulations




Prostate cancer is one of the most common types of cancer in American men,
second to skin cancer (American Cancer Society, 2020). About 1 man in 8 will be
diagnosed with prostate cancer during his lifetime. It is also the second leading
cause of cancer death for American men, behind only lung cancer. Though prostate
cancer can be a serious disease, most men diagnosed with prostate cancer do not die
from it. In fact, about 1 man in 41 will die of prostate cancer. The Surveillance,
Epidemiology, and End Results (SEER) registry tracks 5-year relative survival rates
for prostate cancer in the United States, based on the disease stage at diagnosis
(localized, regional and distant). For those diagnosed with prostate cancer between
2010 and 2016, 5-year relative survival rate is almost 100% for patients diagnosed at
the localized/regional stage, while it is only 30% for those diagnosed at the distant
stage (SEER, 2020). Thus, to prolong cancer survival, early diagnosis is important.
Screening in the population can bring life-saving benefit via early diagnosis and
early treatment, yet it may also cause overdiagnosis and overtreatment (Andriole
et al., 2009). It is thus crucial to assess the balance between benefits and harm-
s associated with screening. Specifically, for prostate cancer, the screening tool is
prostate-specific-antigen (PSA) testing, which entered clinical practice in 1988. Nu-
merous observational studies have reported conflicting findings regarding the benefits
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of screening (Lin et al., 2008). A nation-wide randomized, controlled trial of prostate-
cancer screening was conducted in the U.S. - the Prostate, Lung, Colorectal, and
Ovarian (PLCO) Cancer Screening Trial. For the prostate component of the PLCO
trial, from 1993 through 2001, 76,693 men at 10 U.S. study centers were randomly
assigned to receive either annual screening or usual care as the control (PLCO Trial,
2010). Men in the screening group were offered annual PSA testing for 6 years. Once
diagnosed, the distributions of treatment given were similar in the two groups within
each tumor stage. The subjects were followed up for a maximum of 13 years. Re-
searchers found that while PSA tests led to increased incidence of cancer diagnosis,
their effect on prostate cancer mortality was in doubt (Andriole et al., 2012). In 2012,
the U.S. Preventive Services Task Force (USPSTF) determined that there was “very
low probability of preventing a death from prostate cancer in the long term” and
recommended against routine use of the test (Force et al., 2008).
It is the purpose of this dissertation to assess the screening effect on cancer mor-
tality. Generally, screening tests affect both cancer diagnosis and death through the
following mechanism:
Figure 1.1: Diagram illustrating the disease progression process with screening tests.
1. Cancer diagnosis may occur earlier at potentially earlier stages with screening
tests.
2. Assume once diagnosed, specific appropriate treatment will be given, and treat-
ment is confounded by indication provided by the cancer diagnosis.
2
3. Cancer severity at diagnosis and the following treatment received will affect
cancer mortality.
Mathematically speaking, we will test the null hypothesis H0: NO screening bene-
fit on cancer mortality, despite a profound screening effect on the timing of treatment
occurring at diagnosis. Here, intermediate (cancer diagnosis) and terminal (cancer
death) events are driven from a common disease progression process, thus holding a
strong relationship. A joint modeling approach can be adopted to model both events
simultaneously while considering this relationship, which characterizes the disease
natural history. Moreover, its predictive capability of prognosis and survival rate
provides important insights for optimal treatment decisions. Therefore, we test the
screening effect on cancer mortality with joint modeling of cancer diagnosis and death.
The key to establishing a joint model is to characterize the relationship between
intermediate and terminal events. Dependent on this relationship, a number of meth-
ods have been proposed.
• Semicompeting risk: It denotes the mechanism where the terminal event may
censor the intermediate event, but not vice versa. The correlation between
events can be captured through copulas (Clayton, 1978; Fine et al., 2001; Chen,
2012) and illness-death models (Andersen et al., 1991, 2012; Xu et al., 2010;
Kalbfleisch and Prentice, 2011). The reason why these methods do not work in
our scenario is that the intermediate and terminal events are unordered. For
example, the terminal event is death due to metastases; while the intermediate
event is defined as local recurrence, which does not necessarily precede the
terminal.
• Recurrent events: It denotes the mechanism where intermediate always pre-
cedes terminal event, which satisfies the time ordering of the events. Gap time
analysis (Lin et al., 1999; Huang and Liu, 2007; Shu and Schaubel, 2016) is
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a typical analysis method. It jointly models time-to-intermediate and the gap
time between time-to-intermediate and time-to-terminal. Yet our null hypoth-
esis is to test the screening effect on the marginal terminal event, which is not
directly modeled with gap time analysis. Thus, this method is not compatible
with our null hypothesis. Alternatively, the order restriction can be imposed by
a conditional argument restricting the domain of an unordered joint distribu-
tion of time-to-intermediate and time-to-terminal to the upper wedge. However,
with this model, due to positive dependence between intermediate and terminal
events, we cannot make the covariate affect one event while not affecting the
other, which excludes our null hypothesis.
The difficulty in designing joint models to test the null hypothesis lies in the gener-
al positive dependence induced by diagnosis always preceding death. Traditional joint
models dealing with this dependence usually let an effect on the diagnosis propagate
through the dependence structure to the terminal event, thus excluding the null hy-
pothesis. Throughout this dissertation, we focus on developing semiparametric joint
models incorporating the null hypothesis.
In Chapter II, the proposed joint model is composed of two parts; one is to char-
acterize the marginal death distribution, and the other is for conditional incidence
of diagnosis given death. The marginal death model enables us to test the screening
effect in a straightforward way; while for the conditional model, due to the time order-
ing of the two events, the parametric beta distribution is a natural choice to provide
limited support for the incidence event. Nonparametric maximum likelihood estima-
tion based on semiparametric regression analysis is used for statistical inference, and
asymptotic properties of the proposed estimators are studied using empirical process
and martingale arguments. The methodology is illustrated with simulations and the
PLCO prostate cancer data, combined with uncontaminated controls simulated from
SEER data before PSA.
4
In Chapter III, we extend the proposed parametric conditional model of Chap-
ter II to a semiparametric model based on a multinomial logit model for the incidence
event. The technical difficulty comes from the complex form of a multinomial likeli-
hood. EM algorithm can be viewed as a way to replace maximization of the original
observed likelihood by the corresponding complete-data likelihood, which may offer
computational advantage and increased stability. With this idea in mind, an artificial
latent variable is introduced to transform the multinomial likelihood to Poisson-type
(Baker, 1994; Lang, 1996; Tsodikov and Chefo, 2008), and an EM algorithm, treating
the artificial variable as missing data, is derived to simplify the maximization step
to obtain the maximum likelihood estimators (MLE). To illustrate our method, we
study its performance with Monte Carlo simulations and real data analysis.
In Chapter IV, we consider the situation where both incidence of cancer diagnosis
and death are observed, yet the type of incidence (causal to death or not) is missing.
Overdiagnosis is caused if non-causal incidence is detected. This mechanism thus
incorporates the null hypothesis, where screening does not affect cancer mortality,
though it increases the risk of the incidence event. A mechanistic joint model is for-
mulated on the partially observed disease progression process, and a test is developed
for the causal effect of screening. We apply the concept of modulation that describes
how the occurrence of a latent event affects the risk of a future event from the same
cancer progression process in a time-dependent fashion (Cook and Lawless, 2007).
Such formulation results in a strong link and information sharing between cancer
incidence and death, thus providing efficiency gains. A likelihood-based approach is
adopted for statistical inference, and the obtained MLEs are proved to be consistent
and asymptotically efficient. The method is illustrated with numerical examples.
Before starting the next chapter, we will now briefly review some concepts of lead
time and length bias in the context of screening.
Lead time (Gates, 2001) is the amount of time by which a diagnosis has been
5
advanced by screening. In the analysis of survival from diagnosis, lead time constitutes
an artificial addition to the survival time for screen-detected cases. To avoid lead time
bias, the starting point for survival analysis should be taken as the randomization
time, instead of the diagnosis time.
Length bias (Zelen and Feinleib, 1969) is a form of selection bias, where the
diagnostic screen does not detect individuals at random, but detects those with slow-
growing pre-clinical diseases, due to their longer pre-clinical sojourn time. The indi-
viduals picked out by screening will have longer survival, regardless of whether there
is a gain in survival due to treating the disease earlier. The extreme form of length
bias is overdiagnosis, which would never have caused any symptoms or been clinically
detected in the absence of screening. To avoid length bias, when evaluating screening
effects from randomized trials, disease-specific survival of all the individuals in the
screening group and of all the individuals in the control group should be compared.
6
CHAPTER II
Conditional Modeling of Incidence of Cancer
Diagnosis on Terminal Event
2.1 Introduction
Screening in the population can bring life-saving benefits via early diagnosis and
the following early treatment, yet it may also cause overdiagnosis and overtreatmen-
t (Andriole et al., 2009). It is thus crucial to assess the balance between benefits
and potential harms associated with screening. Specifically, for prostate cancer, the
screening tool is prostate-specific-antigen (PSA) testing, which has been widely used
in the United States since the late 1980s. Large randomized trials have been con-
ducted to study the screening effect, including the PLCO (Prostate, Lung, Colorectal,
and Ovarian) and the ERSPC (European Randomized Screening Study of Screening
for Prostate Cancer) trials. Researchers found that while PSA tests led to increased
incidence of cancer diagnosis, their effect on prostate cancer mortality was in doubt
(Andriole et al., 2012). In 2012, the U.S. Preventive Services Task Force (USPSTF)
determined that there was “very low probability of preventing a death from prostate
cancer in the long term” and recommended against routine use of the tests (Force
et al., 2008). In this article, we are interested in evaluating whether screening can
bring benefit on cancer mortality, despite a profound effect on the timing of treatment
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occurring at diagnosis.
Motivated by the idea that there is a common process driving the intermediate (in-
cidence of cancer diagnosis) and the terminal (cancer death) events, a joint modeling
approach is needed to capture the relationship between the two events. Semicompet-
ing risks (Fine et al., 2001) can model events where the terminal event may censor the
intermediate one, but not vice versa (e.g, metastasis and death from local disease);
yet fail to model sequential events, as in our scenario. Multi-state models (Andersen
et al., 1991, 2012; Kalbfleisch and Prentice, 2011) use transition intensities to model
the process where subjects move from one state to the next, thus depicting the event
history. This class of models can be easily adapted to different data structures. X-
u et al. (2010) proposed an illness-death model with a shared frailty to model the
semicompeting risks data. The multi-state model proposed by Dejardin et al. (2010)
with two events, progression and death, assumed an ordering to the two events. Yet,
due to the positive dependence between intermediate and terminal events, we cannot
make the covariate affect one event while not affecting the other with this model,
which excludes our null hypothesis. Gap time analysis (Lin et al., 1999; Schaubel and
Cai, 2004; Huang and Liu, 2007; Shu and Schaubel, 2016) is also a typical method to
analyze data with or without ordering. It jointly models the time to the intermediate
event and the gap time between time-to-intermediate and time-to-terminal events.
Yet our null hypothesis is to assess the covariate effect on the terminal event, which
is not directly modeled with gap time analysis.
Kong et al. (2018) conditionally modeled longitudinal data with terminal event
to provide an intuitive and meaningful interpretation of the effect of the terminal
event on the longitudinal measures in the joint analysis. Motivated by this idea,
we propose a semiparametric joint model with two parts: one is to characterize the
marginal death distribution, and the other is for conditional incidence of diagnosis
given death. The marginal death model enables us to test the screening effect in an
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explicit way, and the conditional model can provide limited support for the incidence
event, such that incidence always precedes death. Statistical inference is based on
nonparametric maximum likelihood estimation.
The rest of the chapter is organized as follows. Section 2.2 describes the framework
of our proposed model and derives its essential distributional characteristics. Section
2.3 presents the likelihood in counting process form and the corresponding martingale
properties, as well as the estimating procedure for the nonparametric maximum like-
lihood estimators. The asymptotic properties are outlined in Section 2.4, with proofs
given in the Appendix A.5. Section 2.5 conducts simulation studies, evaluating the
performance of the proposed estimators with finite samples. Section 2.6 analyzes the
prostate cancer data. Finally, we discuss the results in Section 2.7.
2.2 Model and Likelihood
2.2.1 Data Structure and Notation
Consider two sequential events, such as incidence of cancer diagnosis and cancer
death, in our model. Let TI and TD be the time-to-incidence and time-to-death,
respectively; z be a set of fully observed covariates; and C be the censoring time
which is independent of TI and TD given z. For the sequential events, the underlying
assumption is incidence must precede the terminal event, i.e. TD > TI w.p. 1.
We observe (X1,∆1, X2,∆2), where X1 = min(TI , C) is the time to the interme-
diate event (i.e. incidence or censoring); X2 = min(TD, C) is the time to the terminal
event (i.e. death or censoring); ∆1 = 1(X1 = TI) is the indicator of observing inci-
dence; and ∆2 = 1(X2 = TD) is the indicator of observing death.
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2.2.2 Model Specification
We formulate our model in two parts. The first is to characterize marginal distri-
bution of death with a Cox proportional hazards model, and the second is to model
the conditional distribution of incidence given death via beta distribution:













, 0 < t < tD. (2.2)
Here, B(a(z), b(z)) is a beta function parameterized by a(z) and b(z). Covariates
z enter the model through η, a and b. Specifically, we have η(z) = eβηz, a(z) = eβaz,
b(z) = eβbz, and β = (βη, βa, βb) is the combined vector of regression coefficients.
The cumulative baseline hazard H(t) summarizes the underlying disease progression
pattern leading to a terminal event.
Beta distribution is a natural choice to provide limited support for TI ∈ (0, TD),
which ensures that incidence always precedes death. The proposed model directly
specifies marginal death, which incorporates our null hypothesis and enables us to
test the screening effect on marginal death in a straightforward way.
It may be observed that if TD goes to infinity, the conditional distribution of
incidence becomes 0, which restricts the support of TD to be finite. Suppose tlf is the
last observed failure of death. We set a threshold τ , and assume that for individuals
with terminal events censored after tlf , they live up to time τ . Note τ is the time
specified after tlf .
2.2.3 Likelihood Construction
We combine (2.1) and (2.2) to build the joint likelihood of cancer diagnosis inci-
dence and death. The likelihood of a single subject with observed data (X1,∆1, X2,∆2)
falls into one of the following scenarios:
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1. Subject has incidence at X1, and dies at X2 (i.e. ∆1 = 1, ∆2 = 1):





























2. Subject has incidence at X1, and is censored at X2 (i.e. ∆1 = 1, ∆2 = 0):
• If X2 > tlf ,













= e−ηH(tlf )fbeta(X1; τ, a, b).








ηe−ηH(tD)fbeta(X1; tD, a, b)dH(tD) + e
−ηH(tlf )fbeta(X1; τ, a, b).
3. Subject is censored at X2 before any event is observed (i.e. ∆1 = ∆2 = 0):
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fTD(tD)fTI |TD(tI |tD) dtIdtD +
τ∫
X2


















We can alternatively express the joint log-likelihood for a single subject as:






fTI (X1)STD|TI (X2|TI = X1)
]
+ (1−∆1) logSTI (X1)
= ∆1 log fTI (X1) + (1−∆1) logSTI (X1)
+ ∆1
[
∆2 log fTD|TI (X2|X1) + (1−∆2) logSTD|TI (X2|TI = X1)
]
. (2.3)
The joint log-likelihood can be partitioned into two parts, such that the contribution
from incidence is separated from terminal event. If we can denote l1 and l2 as the
quantities in each line of equation (2.3), it is easy to see that l1 is based on information
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from incidence, while l2 is based on additional information from the subsequent time
segment between incidence and death.
2.2.4 Prediction of Death Given Incidence
The model also allows us to make predictions of the distribution of the time
to the terminal event, given observed incidence information. This is of particular
interest to clinical practice, as it allows us to predict survival for a subject who
has/ has not been diagnosed after some specified time t∗. Derived in Appendix A.1
is the predicted conditional survival functions for death given patient’s diagnosis
information. Specifically, we have the survival functions






∗; tD, a, b)dH(tD) + e
−ηH(tlf )fbeta(t
∗; τ, a, b)∫ tlf
t∗
ηe−ηH(tD)fbeta(t∗; tD, a, b)dH(tD) + e−ηH(tlf )fbeta(t∗; τ, a, b)
, t ≥ t∗
1, t < t∗
(2.4)
for a subject who has been diagnosed at t∗, and































] , t ≥ t∗
1, t < t∗
(2.5)
for a subject who has not been diagnosed until t∗.
2.3 Estimation
The proposed model is semiparametric, consisting of a parametric component β
for covariate effects and nonparametric components H(·) for baseline hazard of death.
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H(·) is a non-decreasing step function with jumps {dH} only at the observed death
times. Let us denote the full parameter set Ω = (β, {dH}). We use the EM algorithm
(Tsodikov (2003), Rice and Tsodikov (2017)) and profile likelihood (Murphy and
Van der Vaart (2000)) approach to obtain the nonparametric maximum likelihood
estimator (NPMLE) for Ω.
2.3.1 Martingale Theory
In counting process notation, for subject i, let N1i(t) = 1(X1i ≤ t,∆1i = 1)
and Y1i(t) = 1(X1i ≥ t) be the observed counting process and at risk process for
incidence, respectively; let N2i(t) = 1(X2i ≤ t,∆2i = 1) and Y2i(t) = 1(X2i ≥ t)
denote the observed counting process and at risk process for death. Log-likelihood





















The martingales dM1i(t) and dM2i(t|t1) can be constructed based on observed
counting processes with respect to filtration Fi(t−) = σ
{
N1i(s), N2i(s), Y1i(s), Y2i(s),
zi : s ∈ [0, t)
}
as
dM1i(t) = dN1i(t)− Y1i(t)dΛ1i(t),







−ηiH(tD)fbeta(t; tD, ai, bi)dH(tD) + e

















−ηiH(t)fbeta(t1; t, ai, bi)∫ tlf
t
ηie−ηiH(tD)fbeta(t1; tD, ai, bi)dH(tD) + e−ηiH(tlf )fbeta(t1; τ, ai, bi)
dH(t)
, Θ2i(t; t1)dH(t).
dΛ1i(t) is the hazard of subject i having incidence at time t, and dΛ2i(t|t1) is the
hazard of subject i dying of cancer at time t, given incidence at time t1. They can be
derived through the following probabilistic argument:
E{dN1i(t)|Fi(t−)} = Y1i(t)Pr{dN1i(t) = 1|Y1i(t) = 1} = YIi(t)dΛ1i(t),
and E{dN2i(t|t1)|Fi(t−)} = Y2i(t)Pr{dN2i(t|t1) = 1|Y2i(t|t1) = 1} = Y2i(t)dΛ2i(t|t1)
(see Appendix A.2 for more details).
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2.3.2 Score Functions and NPMLE


















As in Hu and Tsodikov (2013), for a functional J(f), f = f(x), the functional









Applying the functional derivative to the full log-likelihood (2.6), with respect to
the infinite-dimensional parameters {dH(s)}, we can obtain the score function for























which is a martingale under the true model.
Taking derivative of the log-likelihood, with respect to the regression parameter
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which is also a martingale under the true model.
Set score functions (2.7) and (2.8) to be zero, and solve them, can give the NPMLE
Ω̂ = (β̂, {dĤ}).
2.3.3 Estimation Procedure - EM Algorithm
The NPMLE can be obtained using (β̂, {dĤ}) = argmaxβ,{dH} l(β, {dH}). How-
ever, it is unpleasant to directly maximize, since the nonparametric parts {dH} are
of infinite-dimension. Instead, we apply the profile likelihood to estimate β and
{dH} jointly. We first obtain the estimators of {dH} with fixed β. Then replacing
{dH} in the observed log-likelihood l(β, {dH}) with {dĤ(β)}, we have the profile




. Finally, the finite-dimensional parameter β is
estimated by maximizing the resulting profile likelihood over β.
The key step is to obtain the estimator of {dH}, given β. We use EM algorithm
to estimate the baseline hazards. Derivation of EM algorithm for our model is shown


















Ψ(s) = 1(X2 ≤ tlf )
{
Y2(s)η + [1− Y2(s)](1−∆2)
[
∆1
ηU(s−, tlf ) + ηV − U.s
U(X2, tlf ) + V
+ (1−∆1)
ηW (s−, tlf ) + ηZ −W.s
W (X2, tlf ) + Z
]}
+ 1(X2 > tlf )η,
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U(X2, tlf ) + V
+ (1−∆1)
W.s
























































































dH(s) are updated iteratively, k = 0, 1, 2, ..., until convergence, i.e., dH(k+1) → dH(k).
Note, at convergence, the second term of (2.9) disappears, leaving the estimating
equation the same as that obtained from observed data; also estimators are consistent
(Tsodikov (2003)).
The estimation procedure is described as follows:
Start with β(0) = 0, j = 0.
1. Maximize the likelihood over H(β), given β = β(j):
(a) Set k = 0. Initialize dĤ(0)(s) such that all jumps in the baseline hazards
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have equal size, respectively.
(b) With β fixed, calculate dĤ(k+1)(s) using equations above.




2. Maximize the profile log-likelihood lpr(β) = l(β, {dĤ(β)}) over β:
(a) Calculate profile log-likelihood l(β, {dĤ(β)}).
(b) Find β(j+1) by maximizing lpr(β) over β, i.e. β
(j+1) = argmaxβ lpr(β), using
numerical optimization method, e.g. Broyden-Fletcher-Goldfarb-Shanno
algorithm (BFGS).
Iteratively apply steps 1-2 to estimate β, until convergence of lpr(β)
lpr(β
(j+1))− lpr(β(j)) < ξ.
Note the convergence tolerance for the inner loop (EM algorithm used to estimate
baseline hazards, given β) should be stricter than that for the outer loop, e.g. ε =
10−6, ξ = 10−5.
2.4 Asymptotic Properties
We apply the empirical process (Kosorok, 2008; Van Der Vaart and Wellner, 2000)
and the theory of martingale structure in counting process to build the asymptotic
properties, adapted from previous work (Zeng and Lin, 2007, 2010; Chen, 2009, 2010;
Hu and Tsodikov, 2014; Rice and Tsodikov, 2017).
Assuming regularity conditions hold, in the following, Theorems II.1 and II.2 state
the consistency and weak convergence results of the NPMLE Ω̂, while Theorem II.3
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justifies the use of negative Hessian matrix from profile log-likelihood in variance
estimation. Regularity conditions and proofs are provided in Appendix A.5.
Under regularity conditions,
Theorem II.1. With probability 1: β̂ converges to β0; Ĥ(t) converges to H0(t) uni-






converges weakly to a zero-mean Gaussian
process. In addition, consider a linear functional of Ω̂,
n1/2
{








where a is a real vector, b(t) is a function with bounded total variation in [0, τ ],
evaluated at the observed death times. Let ΦT = (aT , {b(·)}T ). The asymptotic
variance-covariance function of the linear functional above can be consistently es-










li, li is subject i’s observed log-likelihood
defined.
Theorem II.3. The inverse of the negative Hessian matrix of the profile log-likelihood
with respect to β is a consistent estimator of the limiting variance-covariance matrix



























This section presents Monte Carlo simulations to illustrate our proposed method-
ology. The simulation settings were as follows. The true baseline hazard for ter-
minal event was H(t) = 0.1t2. We considered two covariates Z1 and Z2, where
Z1∼Bernoulli(0.5), and Z2∼Normal(0, 1). Covariates entered the model via η(z) =
eβ1z2 , a(z) = eβ2z1+β3z2 , and b(z) = eβ4z1+β5z2 , with true parameters (β1, β2, β3, β4, β5) =
(1, 0.5, 0.3, 0.2,−0.6). Censoring was simulated from the exponential distribution
Exp(0.2), yielding 25% intermediate and 45% terminal events censored.
2.5.1 Finite-sample Properties of Parameter Estimates
We conducted simulations to study the finite-sample properties of the parameter
estimates obtained. Samples of size 200 and 500 were examined, each took two
different values of τ , 1 and 1000 units after the last observed failure time tlf . For each
simulation scenario, 1000 data sets were generated. Standard errors were obtained
from the numerically evaluated Hessian matrix at the solution.
The simulation results are summarized in Table 2.1. Comparing scenarios with
sample size 200 and 500, both with τ = tlf + 1, the proposed estimators appear to
have satisfactory performance for the sample sizes considered, with diminishing bias
for larger sample size and good coverage probability at the 95% nominal level. With
the larger sample size, we see better agreement between asymptotic standard errors
and empirical standard deviations, which validates the performance of the variance
estimators. Comparing scenarios with same sample size 500, yet different choices of
τ (tlf + 1 and tlf + 1000), the estimators both perform well, in terms of small bias,
consistent standard error estimation, and well-maintained 95% coverage probability.
Thus, the proposed estimators are robust to different specifications of τ .
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Table 2.1: Simulation results using the proposed beta model.
N τ β Truth Bias ASE ESD 95% CP
200 +1
β1 1 -0.008 0.119 0.117 0.956
β2 0.5 0.031 0.149 0.153 0.949
β3 0.3 0.003 0.109 0.105 0.936
β4 0.2 0.030 0.164 0.159 0.949
β5 -0.6 -0.004 0.113 0.111 0.938
500 +1
β1 1 -0.005 0.073 0.073 0.962
β2 0.5 0.012 0.098 0.097 0.956
β3 0.3 0.007 0.066 0.065 0.949
β4 0.2 0.007 0.099 0.100 0.938
β5 -0.6 0.007 0.066 0.069 0.967
500 +1000
β1 1 -0.007 0.072 0.072 0.942
β2 0.5 0.009 0.099 0.097 0.951
β3 0.3 0.014 0.069 0.066 0.931
β4 0.2 0.001 0.100 0.100 0.942
β5 -0.6 0.013 0.067 0.070 0.951
ASE: average of estimated standard errors
ESD: empirical standard deviation based on Monte Carlo estimates
95% CP: 95% coverage probability
2.5.2 Hypothesis Testing
Given the proposed estimators, we constructed the likelihood ratio test (LRT) to
test the covariate effect on the terminal event.
H0: z1 does not have an effect on the marginal terminal event.
The simulation set-up was the same as before. Here, sample size was chosen to
be 500 and τ = tlf + 1. The simulation procedure was as follows:
1. Generate a data set under H0.
2. Fit the models with and without covariate z1 entering η, respectively, and obtain
the two log-likelihoods.
3. Calculate the LRT statistic, and decide if H0 is rejected.
4. Repeat steps 1-3 1000 times, and calculate the empirical p-value.
Based on the simulations, the 0.05 significance level is well maintained (0.053).
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2.6 Application to Prostate Cancer Screening Trial Data
2.6.1 Data
The proposed method was applied to the motivating setting of the prostate cancer
screening trial, testing the screening effect on cancer mortality. The data come from
the PLCO trial, with patients entering the trial aged 55-74 years old. The control arm
in the PLCO trial was contaminated (Vickers, 2017), as about 50% of PLCO control
patients had PSA testing before enrollment, and of the remainder, close to 90% had
PSA measured during the trial (Shoag et al., 2016). Researchers described the trial as
comparing “opportunistic versus systematic screening” rather than screening versus
no screening. Thus, we needed to introduce a set of uncontaminated control data
from external data to assess the screening effect. Comparing SEER with PLCO data
(Pinsky et al., 2012), there was no unambiguous evidence showing a healthy volunteer
effect. Therefore, a simulated subset of SEER data, with diagnosis between 1980 and
1987 before the use of PSA as a screening tool, was created to act as uncontaminated
“perfect” controls.
In the combined data set, 76,674 subjects are from PLCO trial (38,335 subjects
in the screening arm, and 38,339 subjects in the control arm), and 38,335 subjects
are from the SEER control arm. For patients from the PLCO trial, 4418 (11.52%) in
the screening arm were diagnosed with prostate cancer, and 145 (0.38%) died of it;
while 4036 (10.53%) in the control arm were diagnosed and 142 (0.37%) died of it.
For patients in the simulated SEER control arm, 2726 (7.11%) were diagnosed with
prostate cancer, and 606 (1.58%) died of it. Maximum follow-up time was 13 years.
From the data, we have information about time-to-diagnosis and time-to-death. In
addition to arm (screening/control) and trial (PLCO/SEER), we are also interested
in studying the age effect, since age is an important risk factor for prostate cancer.
To make patients from different trials comparable, the simulated SEER data have the
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same age distribution as the PLCO data.
2.6.2 Results




The goodness of fit for the Cox regression model for marginal death is checked in
Figure 2.1. From the graphical inspection, there is no pattern for Schoenfeld resid-
uals over time, supporting the proportional hazards assumptions for the covariates
age, arm and trial, with respective goodness of fit p-values of 0.72, 0.92 and 0.58,
respectively.
Table 2.2 shows the regression coefficient estimates for both the proposed join-
t model and the Cox model for marginal death. Based on the estimates of our
proposed joint model, older patients have greater risk of death (β=0.53, HR=1.69,
p-value<0.0001), and screening helps reduce cancer mortality (β=-1.16, HR=0.31,
p-value<0.0001). Due to the relatively small number of deaths, which may lead to
lack of power to detect any difference between arms, and the contamination of PLCO
control arm, there is no significant difference between PLCO screening and PLCO
control arms.
Regarding the analysis of time-to-death, theoretically, point estimates of βη’s
should be similar for the two models; as the table shows, the model results are as
expected. The standard errors for βη’s in the proposed method are slightly smaller
than that from the marginal model, since we utilize information from incidence of
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Figure 2.1: Goodness of fit of the Cox regression model for marginal death. The solid
line plots the log hazard ratio of the corresponding covariate over time, and the red
dots are scaled Schoenfeld residuals.
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diagnosis to gain efficiency. Our proposed model allows a bigger picture of disease
progression process, as it incorporates incidence data, while the simple Cox model for
marginal death does not.
Table 2.2: Prostate cancer screening trial analysis.
(a) Log-hazard ratio for time-to-death (βη)
Proposed Joint Model Cox for Marginal Death
Parameter Est. SE p-value Est. SE p-value
Age 0.528 0.033 < 0.0001 0.529 0.034 < 0.0001
PLCO scr vs. PLCO control 0.031 0.117 0.791 0.021 0.118 0.861
PLCO control vs. SEER control -1.155 0.094 < 0.0001 -1.148 0.094 < 0.0001
(b) Parameter estimate for time-to-incidence given death (βa, βb)
Proposed Joint Model
Parameter Est. SE p-value
βa0 0.607 0.023 < 0.0001
βa1 -0.152 0.011 < 0.0001
βa2 -0.269 0.024 < 0.0001
βa3 -0.629 0.028 < 0.0001
βb0 -1.775 0.038 < 0.0001
βb1 0.017 0.017 0.326
βb2 -0.240 0.037 < 0.0001
βb3 -0.188 0.046 < 0.0001
To assess model fit (Dejardin et al., 2010), Figure 2.2 and 2.3 present the survival
estimates for time-to-diagnosis and time-to-death, respectively, for subjects who en-
tered the study at age 67, stratified by arm and trial. Both of the figures have plots of
marginal survival functions obtained using the proposed model, which closely match
the KM estimates obtained from the observed data, confirming the validity of the
model.
2.6.3 Prediction of Death Given Diagnosis
We can also use the proposed joint model to predict cancer mortality given diag-
nosis information, which is of particular interest to clinical practice. Equations (2.4)
and (2.5) allow us to calculate this conditional survival function and produce the
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Figure 2.2: Survival estimates for time-to-diagnosis for subjects who entered the
study at age 67. Proposed model (dotted lines) closely matches Kaplan-Meier (KM)
estimates (solid lines).
Figure 2.3: Survival estimates for time-to-death for subjects who entered the study at
age 67. Proposed model (dotted lines) closely matches Kaplan-Meier (KM) estimates
(solid lines).
27
plots shown in Figure 2.4. Figure 2.4 presents the predicted survival rates stratified
by arm and trial, given diagnosis status (diagnosed and not diagnosed) after 1 year
of randomization, among men who entered the study at age 67. We can see that giv-
en the same diagnosis information, patients without screening (SEER control) have
much greater risk of death, compared with those with screening (PLCO trial). The
PLCO screening arm and PLCO control arm present no surprise and show little d-
ifference in predicted survival rates. In addition, note that the survival probabilities
for patients with NO cancer diagnosed at 1 year (right plot) are very close to 1, while
those with cancer diagnosed (left plot) are not. Thus, in comparison with patients
with NO cancer detected, patients with cancer detected are more likely to die from
it, as expected.
Figure 2.4: Predicted survival estimates for death from prostate cancer, given diag-
nosis status after 1 year of randomization, among men who entered the study at age
67. Left figure is for a hypothetical subject who has prostate cancer diagnosed at the
time indicated, while the right one is for a subject not diagnosed at that time.
2.7 Discussion
We have presented a framework to test the screening effect on cancer mortality
with a semiparametric joint model of ordered events. Within the proposed model, the
NPMLE can be obtained by EM algorithm and profile likelihood, and its asymptotic
28
properties established. Simulation studies with different scenarios indicate good finite
sample performance. Application of the proposed model to the PLCO prostate cancer
data, combined with simulated SEER control data, reveals the benefit of screening
on reducing cancer mortality.
The traditional joint models usually let an effect on the diagnosis propagate
through the dependence structure to the terminal event, thus excluding the nul-
l hypothesis. Our proposed model specifies marginal distribution of death directly,
thus allowing testing of the screening effect on marginal death in a straightforward
way. Although in the model specification, we set a threshold τ such that no death
happened after it, this is a typical assumption when asymptotic properties are proved
in survival analysis. Moreover, the proposed estimators are robust with different
specifications of τ . In fact, we can assign a very large value to τ , and in a practical
sense, we can say there is no upper limit for the terminal event.
The beta conditional incidence model provides limited support for the incidence
event, such that the joint pdf is zero when death precedes incidence, which is a true
reflection of the sequential mechanism. The conditional model can also be specified
with other parametric distributions, such as Weibull, or be extended to a semipara-
metric model to offer more flexibility.
Compared with the model on marginal death, our joint model provides a predictive
utility to help with clinical practice. In addition, it has slight efficiency gain, due to
the extra information from observations with incidence observed, yet death censored.
In future work, it would be of interest to further improve efficiency, by assuming a
stronger relationship between the two events.
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CHAPTER III
A Semiparametric Joint Model for Estimating the
Screening Effect on Cancer Mortality
3.1 Introduction
Prostate-specific-antigen (PSA) testing, a screening tool for prostate cancer, has
been widely used in the United States since the late 1980s. Treatment for prostate
cancer can be confounded by indication provided by the cancer diagnosis that can
occur earlier with PSA screening. While PSA tests led to increased incidence of
cancer diagnosis, their effect on prostate cancer mortality is disputed (Andriole et al.,
2012).
In this chapter, we test the screening benefit on cancer mortality regardless of a
profound effect of screening on the timing of treatment occurring at cancer diagno-
sis. We extend the proposed parametric conditional incidence model in Chapter II to
a semiparametric model to relax the parametric assumptions, thus providing wider
applicability and increased robustness. The sequential mechanism of incidence pre-
ceding death can be interpreted mathematically as
TD∫
0
fTI |TD(t|TD)dt = 1.
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In discrete time survival analysis, it can be alternatively written as
∑
k:0<tk≤TD
Pr(TI ∈ [tk, tk + dt)|TD) = 1.
Here time before death is split into several non-overlapping time intervals, and [tk, tk+
dt) is the kth interval. The equation indicates that the summation of probabilities of
time-to-incidence falling into any time interval before death is 1, which has a similar
form as the constraint of a multinomial logit model. Therefore, a multinomial logit
model is considered for the incidence event.
The computation in the multinomial logit model is costly, especially when the out-
come has a large number of categories as in our case, since it involves high-dimensional
integration and maximization. A number of approaches have been developed to over-
come the computational difficulties. Baker (1994) proposed to transform the multi-
nomial likelihood to a Poisson likelihood to reduce the complexity of the likelihood
function and simplify maximization at the cost of augmenting the model parameters.
This approach, however, inflates the model dimension and increases computational
difficulties. Breslow and Clayton (1993) considered penalized quasi-likelihood estima-
tion to avoid the complex form of multinomial likelihood. Rabe-Hesketh et al. (2002)
applied Gaussian quadrature to numerically approximate multidimensional integrals
in the multinomial problem. Tsodikov and Chefo (2008) introduced an artificial latent
variable to transform the multinomial likelihood to a Poisson likelihood by means of
expectation, and used the self-consistency framework (Tsodikov, 2003) to apply EM
algorithm for estimation. Although this approach introduces an artificial variable, it
is averaged over in the E step and does not need to be estimated. In addition, the
M step takes factorization of the model dimension and thus provides computational
advantages.
We extend Tsodikov and Chefo (2008) to model the incidence event given death,
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where outcome is a time-to-event variable and number of categories for the outcome
is not pre-specified and varies with each subject. Treating the artificial variable and
censored observations as missing data, an EM algorithm is derived for parameter
estimation. Section 3.2 specifies the proposed model and derives its essential distri-
butional characteristics. Section 3.3 presents the likelihood in counting process form
and the corresponding martingale properties, as well as the estimating procedure for
the nonparametric maximum likelihood estimators. The asymptotic properties are
outlined in Section 3.4. Section 3.5 demonstrates the performance of the proposed
estimators with finite samples in simulation studies. Section 3.6 analyzes the prostate
cancer data. Discussion follows in Section 3.7.
3.2 Model and Likelihood
3.2.1 Data Structure and Notation
Let TI and TD be the time-to-incidence and time-to-death, respectively; z be a
set of fully observed covariates; and C be the censoring time which is independent of
TI and TD given z. For the sequential events, the underlying assumption is incidence
must precede the terminal event, i.e. TD > TI w.p. 1.
We observe (X1,∆1, X2,∆2), where X1 = min(TI , C) is the time to the interme-
diate event (i.e. incidence or censoring); X2 = min(TD, C) is the time to the terminal
event (i.e. death or censoring); ∆1 = 1(X1 = TI) is the indicator of observing inci-
dence; and ∆2 = 1(X2 = TD) is the indicator of observing death. tlf1, tlf2 are the last
observed failures of incidence and death, respectively.
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3.2.2 Model Specification
We formulate the model in two parts. The first is the marginal distribution of
death TD with a Cox proportional hazards model
dΛTD(t|z) = η(z)dH(t), (3.1)
where η characterizes covatiate effects on the terminal event TD through η(z) = e
βηz,
and the cumulative baseline hazard H(t) summarizes the disease progression pattern
leading to death.
The second part of the model is the conditional distribution of incidence TI given
time-to-death TD. To ensure that incidence always precedes death, integration of the
distribution of TI over [0, TD] should be 1. If the discrete time survival analysis is
considered, it is natural to use a multinomial logit model to characterize this distri-
bution. To deal with continuous time, a continuous counterpart of the multinomial
logit model is specified. Assuming time 0 is the reference category, given TD, the logit
compares any time t with the reference category as
log
fTI |TD(t|TD, z)
Pr(TI = 0|TD, z)
= log h̃(t) + βµ(t)z, 0 < t ≤ TD,
where βµ(t) is a parametric function of time t, representing time-dependent regression
coefficients for TI = t; h̃(t) is an arbitrary function of time t, and h̃(t) ≥ 0. Define
µ(t|z) = eβµ(t)z, we have






, 0 < t ≤ TD,







For the rest of the chapter, we omit z as an argument for brevity and denote η(z) by
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η and µ(t|z) by µ(t).
3.2.3 Discretization of the Conditional Incidence Model
For semiparametric estimation, we work with discrete time survival analysis, so it
is of interest to discretize the incidence models (3.2).
Given data, incidence events happen at sorted time points
0, t1, t2, ..., tn.
Split [0, TD] based on these time points, and obtain intervals as
0, (0, t1], (t1, t2], ...
and k represents the kth interval. The conditional model can be rewritten as
If 0 < t ≤ TD,













Since each interval is infinitely small, h̃(tk) and µ(tk) is constant within the interval.
Define h(t) , h̃(t)dt, we have






, 0 < t ≤ TD






, t = 0. (3.3)
The discrete model takes the form of a multinomial logit model. The summation
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of probabilities of TI falling into any time interval between 0 and TD is 1. Also,
there is a point mass for TI at time 0, and h0µ0 is restricted to 1 for identifiability.
Moreover, βµ(t) is an analog of columns of regression coefficients in the multinomial
logit model. However, since the model might be non-identifiable due to the sparse
categories, instead of allowing βµ(t) to be nonparametric at different incidence times,
we introduce additional parametric restrictions for βµ(t) to be a function of time, to
ensure the model stability.
3.2.4 Likelihood Construction
We combine (3.1) and (3.3) to build the joint likelihood of cancer diagnosis inci-
dence and death. The likelihood of a single subject with observed data (X1,∆1, X2,∆2)
falls into one of the following scenarios:
1. Subject has incidence at X1, and dies at X2 (i.e. ∆1 = 1, ∆2 = 1):







2. Subject has incidence at X1, and is censored at X2 (i.e. ∆1 = 1, ∆2 = 0):
• If X2 ≥ tlf ,





























3. Subject is censored at X2 before any event is observed (i.e. ∆1 = ∆2 = 0):
• If X2 ≥ tlf1,







• If X2 ≥ tlf2 and X2 < tlf1,









• If X2 < tlf2 and X2 < tlf1,























We can alternatively express the joint log-likelihood for a single subject as:






fTI (X1)STD|TI (X2|TI = X1)
]
+ (1−∆1) logSTI (X1)
= ∆1 log fTI (X1) + (1−∆1) logSTI (X1)
+ ∆1
[
∆2 log fTD|TI (X2|X1) + (1−∆2) logSTD|TI (X2|TI = X1)
]
. (3.4)
The joint log-likelihood can be partitioned into two parts, such that the contribution
from incidence is separated from terminal event. If we can denote l1 and l2 as the
quantities in each line of equation (3.4), it is easy to see that l1 is based on information
from incidence, while l2 is based on additional information from the subsequent time
segment between incidence and death.
3.2.5 Prediction of Death Given Incidence
The model also allows us to make predictions of the distribution of the time
to the terminal event, given observed incidence information. This is of particular
interest to clinical practice, as it allows us to predict survival for a subject who
has/ has not been diagnosed after some specified time t∗. Derived in Appendix B.1
is the predicted conditional survival functions for death given patient’s diagnosis
information. Specifically, we have the survival functions
• If t ≥ t∗,





























for a subject who has been diagnosed at t∗, and








































for a subject who has not been diagnosed until t∗.
• If t < t∗, since death must happen after incidence, for any subject, whether
diagnosed or not at time t∗,
Pr(TD > t|X1 = t∗,∆1) = 1.
3.3 Nonparametric Maximum Likelihood Estimation
The proposed model is semiparametric, consisting of parametric components
β = (βη, βµ) and nonparametric components {h(t)} and {H(t)}. h(·) is a non-negative
function with nonzero values only at the observed incidence times; H(·) is a non-
decreasing step function with jumps {dH} only at the observed death times. Let us
denote the full parameter set Ω = (β, {h(t)}, {dH(t)}).
3.3.1 Martingale Theory
In counting process notation, for subject i, let N1i(t) = 1(X1i ≤ t,∆1i = 1)
and Y1i(t) = 1(X1i ≥ t) be the observed counting process and at risk process for
incidence, respectively; let N2i(t) = 1(X2i ≤ t,∆2i = 1) and Y2i(t) = 1(X2i ≥ t)
denote the observed counting process and at risk process for death. Log-likelihood
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The martingales dM1i(t) and dM2i(t|t1) can be constructed based on observed
counting processes with respect to filtration Fi(t−) = σ
{
N1i(s), N2i(s), Y1i(s), Y2i(s),
zi : s ∈ [0, t)
}
as
dM1i(t) = dN1i(t)− Y1i(t)dΛ1i(t),
























































dΛ1i(t) is the hazard of subject i having incidence at time t, and dΛ2i(t|t1) is the
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hazard of subject i dying of cancer at time t, given incidence at time t1. They can be
derived through the following probabilistic argument:
E{dN1i(t)|Fi(t−)} = Y1i(t)Pr{dN1i(t) = 1|Y1i(t) = 1} = YIi(t)dΛ1i(t),
and E{dN2i(t|t1)|Fi(t−)} = Y2i(t)Pr{dN2i(t|t1) = 1|Y2i(t|t1) = 1} = Y2i(t)dΛ2i(t|t1).
(see Appendix B.2 for more details)
3.3.2 Score Functions and NPMLE
Define partial derivatives of Θ1i(t) and Θ2i(t; t1), with respect to {h(s)}, {dH(s)}

























Applying the functional derivative (Hu and Tsodikov, 2013) to the full log-likelihood
(3.5), with respect to the infinite-dimensional parameters {h(s)} and {dH(s)}, we













































which are both martingales under the true model.
Taking derivative of the log-likelihood, with respect to the regression parameter


















which is also a martingale under the true model.
Set score functions (3.6), (3.7) and (3.8) to be zero, and solve them, can give the
NPMLE Ω̂ = (β̂, {ĥ(t)}, {dĤ(t)}).
3.3.3 Estimation Procedure
It is computationally difficult and costly to directly solve the score equations
for the full parameter set Ω to obtain the NPMLE, due to the infinite-dimensional
parameters {h(t)} and {dH(t)} in Ω. Instead, it can be obtained using the profile
likelihood approach. This is accomplished by applying an EM algorithm (Tsodikov,
2003) to obtain the implicit estimators for {ĥ(β)}, {dĤ(β)} that depend on β. To
provide computational advantage and increased stability, an artificial latent variable
is introduced to transform the multinomial likelihood to Poisson-type (Baker, 1994;
Lang, 1996; Tsodikov and Chefo, 2008), and an EM algorithm, treating the artificial
variable as missing data, is derived to simplify the maximization step to obtain the
maximum likelihood estimators.
We can artificially construct the conditional incidence model as a mixture model
fTI |TD(tI |tD) = EU
[




where U is a random variable representing artificial missing data, and U∼Exp(1).
Since

























which takes the form of a Poisson-type likelihood.
After this transformation, an EM algorithm is applied to estimate the nonpara-
metric components {dH} and {h}, holding β fixed. Derivation of the EM algorithm
is presented in Appendix B.3. It gives us the score functions for {h} and {dH} at




















− η + Y2(s)η + [1− Y2(s)]
η[U(s−, tlf2) + V ]− U.s
U(X2, tlf2) + V
}
+(1−∆1)1(X1 < tlf1)1(X2 < tlf2)
{
− η + Y2(s)η
+ [1− Y2(s)]
η[W (s−, tlf2) + Z]−W.s
W (X2, tlf2) + Z
}
,




U(X2, tlf2) + V
+ 1(X1 < tlf1)(1−∆1)
W.s





















+ 1(X2 < tlf1)1(X2 < tlf2)
−T + Y2(s)(R + V )− [1− Y2(s)]Ylf2(s)S2








Q+ Y2(s)P (X2, tlf2) + [1− Y2(s)]Ylf2(s)P (s−, tlf2)
















































































































































Equations (3.11) and (3.12) solve for h(s) and dH(s) iteratively, k = 0, 1, 2, ..., until
convergence, i.e., h(k+1) → h(k), dH(k+1) → dH(k). Note, at convergence, the last
term in equations (3.9) and (3.10) disappears, and the estimating equations are the
same as that obtained from observed data. Estimators at convergence are consistent
(Tsodikov (2003)).
The estimation procedure is described as follows:
Start with β(0) = 0, j = 0.
1. Maximize the likelihood over h(β) and H(β), respectively, given β = β(j):
(a) Set k = 0. Initialize ĥ(0)(s) and ˆdH
(0)
(s) with any positive value, e.g. 1,
at observed incidence and death times, respectively.
(b) With β fixed, calculate ĥ(k+1)(s) and dĤ(k+1)(s) using equations (3.11) and
(3.12).







2. Maximize the profile log-likelihood lpr(β) = l(β, {ĥ(β)}, {dĤ(β)}) over β:
(a) Calculate profile log-likelihood l(β, {ĥ(β)}, {dĤ(β)}).
(b) Find β(j+1) by maximizing lpr(β) over β: β
(j+1) = argmaxβ lpr(β), us-
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ing conventional optimization method, e.g. Broyden-Fletcher-Goldfarb-
Shanno algorithm (BFGS).
Iteratively apply steps 1-2 to estimate β, until convergence of lpr(β)
lpr(β
(j+1))− lpr(β(j)) < ξ
Note the convergence tolerance for the inner loop (step 1) should be stricter than
that for the outer loop (step 2), e.g. ε = 10−6, ξ = 10−5.
3.4 Asymptotic Properties
We apply the empirical process (Kosorok, 2008; Van Der Vaart and Wellner, 2000)
and the theory of martingale structure in counting process to build the asymptotic
properties, adapted from previous work (Zeng and Lin, 2007, 2010; Chen, 2009, 2010;
Hu and Tsodikov, 2014; Rice and Tsodikov, 2017).
Assuming regularity conditions hold, in the following, Theorem III.1 and Theo-
rem III.2 state the consistency and weak convergence results of the NPMLE Ω̂ =
(β̂, {ĥ}, {dĤ}), while Theorem III.3 justifies the use of negative Hessian matrix from
profile log-likelihood in variance estimation. Regularity conditions and proofs are
similar as those in Chap II.
Under regularity conditions,
Theorem III.1. With probability 1: β̂ converges to β0; ĥ(t) and Ĥ(t) converges to
h0(t) and H0(t) uniformly over the interval [0, τ ], respectively. Here, β0, h0(t) and





converges weakly to a zero-
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mean Gaussian process. In addition, consider a linear functional of Ω̂,
n1/2
{













where a is a real vector, b1(t) and b2(t) are functions with bounded total variation in
[0, τ ], evaluated at the observed incidence and death times, respectively. Let ΦT =
(aT , {b1(·)}T , {b2(·)}T ). The asymptotic variance-covariance function of the linear
functional above can be consistently estimated by ΦT (In)−1Φ, where In is the observed










subject i’s observed log-likelihood defined as equation (3.5).
Theorem III.3. The inverse of the negative Hessian matrix of the profile log-likelihood
with respect to β is a consistent estimator of the limiting variance-covariance matrix


























This section presents Monte Carlo simulations to assess our proposed method-
ology. The simulation settings were as follows. The true h(t) = 30t, and the true
cumulative baseline hazard for terminal event was H(t) = 0.1t2.5. We considered two
covariates Z1 and Z2, where Z1∼Bernoulli(0.5), and Z2∼Normal(0, 1). Covariates
entered the model via η(z) = eβ1z1+β2z2 , and µ(t|z) = e(β3t+β4)z1 , with true parameters
(β1, β2, β3, β4) = (0.5,−1, 0.8,−1). Censoring was simulated from the exponential
distribution Exp(0.6), yielding 50% intermediate and 65% terminal events censored.
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3.5.1 Finite-sample Properties of Parameter Estimates
We conducted simulations to examine the finite-sample properties of the param-
eter estimates obtained. Samples of size 300 and 500 were examined, each with 1000
replicates. Standard errors were obtained from the numerically evaluated Hessian
matrix at the solution.
The simulation results are summarized in Table 3.1. The proposed estimators
are almost unbiased and get more accurate as sample size increases. The asymptotic
standard errors (ASE) are close to the empirical standard deviations (ESD), suggest-
ing reasonable approximation of the variance estimators; and with larger sample size,
standard errors are smaller, and we see better agreement between ASE and ESD. The
95% coverage probabilities for all the estimators approach the 95% nominal level for
both sample sizes.
Table 3.1: Simulation results using the proposed semiparametric joint model.
N β Truth Bias ASE ESD 95% CP
300
β1 0.5 -0.012 0.191 0.197 0.963
β2 -1 0.023 0.111 0.116 0.948
β3 0.8 0.084 0.445 0.406 0.942
β4 -1 -0.168 0.767 0.716 0.950
500
β1 0.5 -0.001 0.147 0.151 0.961
β2 -1 0.013 0.087 0.089 0.956
β3 0.8 -0.014 0.315 0.299 0.930
β4 -1 -0.030 0.548 0.524 0.937
ASE: average of estimated standard errors
ESD: empirical standard deviation based on Monte Carlo estimates
95% CP: 95% coverage probability
3.5.2 Hypothesis Testing
Given the proposed estimators, we constructed the likelihood ratio test (LRT) to
test the null hypothesis:
H0: z1 does not have an effect on the marginal terminal event.
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The simulation set-up was the same as before. Sample size was chosen to be 500.
The simulation procedure was as follows:
1. Generate a data set under H0.
2. Fit the models with and without covariate z1 entering η, respectively, and obtain
the two log-likelihoods.
3. Calculate the LRT statistic, and decide if H0 is rejected.
4. Repeat steps 1-3 1000 times, and calculate the empirical p-value.
Based on the simulations, the 0.05 significance level is well maintained (0.048).
3.6 Application to Prostate Cancer Screening Trial Data
3.6.1 Data
The proposed method was applied to the motivating setting of the prostate cancer
screening trial, testing the screening effect on cancer mortality. The data come from
the PLCO trial, with patients entering the trial aged 55-74 years old. The control arm
in the PLCO trial was contaminated (Vickers, 2017), as about 50% of PLCO control
patients had PSA testing before enrollment, and of the remainder, close to 90% had
PSA measured during the trial (Shoag et al., 2016). Thus, we needed to introduce a
set of uncontaminated control data from external data to assess the screening effect.
Comparing SEER with PLCO data (Pinsky et al., 2012), there was no unambiguous
evidence showing a healthy volunteer effect. Therefore, a simulated subset of SEER
data, with diagnosis between 1980 and 1987 before the use of PSA as a screening
tool, was created to act as uncontaminated “perfect” controls.
In the combined data set, 76,674 subjects are from PLCO trial (38,335 subjects
in the screening arm, and 38,339 subjects in the control arm), and 38,335 subjects
are from the SEER control arm. For patients from the PLCO trial, 4418 (11.52%) in
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the screening arm were diagnosed with prostate cancer, and 145 (0.38%) died of it;
while 4036 (10.53%) in the control arm were diagnosed and 142 (0.37%) died of it.
For patients in the simulated SEER control arm, 2726 (7.11%) were diagnosed with
prostate cancer, and 606 (1.58%) died of it. Maximum follow-up time was 13 years.
From the data, we have information about time-to-diagnosis and time-to-death. In
addition to arm (screening/control) and trial (PLCO/SEER), we are also interested
in studying the age effect, since age is an important risk factor for prostate cancer.
To make patients from different trials comparable, the simulated SEER data have the
same age distribution as the PLCO data.
3.6.2 Results
In our proposed method, covariates entered the model through
η(t|z) = eβη1Arm+βη2Trial+βη3Age
µ(t|z) = e(βµ1+βµ2t)Arm+(βµ3+βµ4t)Trial+(βµ5+βµ6t)Age
The goodness of fit for the Cox regression model for marginal death was checked.
The proportional hazards assumptions for the covariates age, arm and trial are sup-
ported, with respective goodness of fit p-values of 0.72, 0.92 and 0.58, respectively.
Table 3.2 presents the regression coefficient estimates for both the proposed joint mod-
el and the Cox model for marginal death. Based on the estimates of our proposed joint
model, older patients have greater risk of death (β=0.55, HR=1.73, p-value<0.0001),
and screening helps reduce cancer mortality (β=-1.30, HR=0.27, p-value<0.0001).
Due to the relatively small number of deaths, which may lead to lack of power to
detect any difference between arms, and the contamination of PLCO control arm,
there is no significant difference between PLCO screening and PLCO control arms.
Regarding the analysis of time-to-death, theoretically, point estimates of βη’s
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should be similar for the two models; as the table shows, the model results are as
expected. The standard errors for βη’s in the proposed method are slightly smaller
than that from the marginal model, and this efficiency gain comes from information
of subjects with incidence observed, yet death censored.
Table 3.2: Analysis of prostate cancer screening trial data.
(a) Log-hazard ratio for time-to-death (βη)
Proposed Joint Model Cox for Marginal Death
Parameter Est. SE p-value Est. SE p-value
Age 0.547 0.032 < 0.0001 0.551 0.032 < 0.0001
PLCO scr vs. PLCO control 0.039 0.117 0.738 0.035 0.118 0.767
PLCO control vs. SEER control -1.303 0.092 < 0.0001 -1.274 0.093 < 0.0001
(b) Parameter estimate for time-to-incidence given death (βµ)
Proposed Joint Model
Parameter Est. SE p-value
βµ1 -0.003 0.001 0.002
βµ2 -1.174 0.102 < 0.0001
βµ3 -0.056 0.002 < 0.0001
βµ4 -0.084 0.153 0.584
βµ5 -0.013 0.001 < 0.0001
βµ6 -0.085 0.040 0.036
To assess model fit (Dejardin et al., 2010), Figure 3.1 and 3.2 present the survival
estimates for time-to-diagnosis and time-to-death, respectively, for subjects who en-
tered the study at age 68, stratified by arm and trial. Both of the figures have plots of
marginal survival functions obtained using the proposed model, which closely match
the KM estimates obtained from the observed data, confirming the validity of the
model.
3.6.3 Prediction of Death Given Diagnosis
The proposed joint model can predict cancer mortality given diagnosis informa-
tion, which is of particular interest to clinical practice. As shown in Section 3.2.5, it
allows us to calculate this conditional survival function and produce the plots shown
in Figure 3.3. Figure 3.3 presents the predicted survival rates stratified by arm and
51
Figure 3.1: Survival estimates for time-to-diagnosis for subjects who entered the
study at age 68. Proposed model (dotted lines) closely matches Kaplan-Meier (KM)
estimates (solid lines).
Figure 3.2: Survival estimates for time-to-death for subjects who entered the study at
age 68. Proposed model (dotted lines) closely matches Kaplan-Meier (KM) estimates
(solid lines).
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trial, given diagnosis status (diagnosed or not diagnosed) after 1 year of random-
ization, among men who entered the study at age 68. We can see that given the
same diagnosis information, patients without screening (SEER control) tend to die
of prostate cancer earlier, compared with those with screening (PLCO trial). The
PLCO screening arm and PLCO control arm present no surprise and show little d-
ifference in predicted survival rates. In addition, note that the survival probabilities
for patients with NO cancer diagnosed at 1 year (right plot) are very close to 1, while
those with cancer diagnosed (left plot) are not. Thus, in comparison with patients
with NO cancer detected, patients with cancer detected are more likely to die from
it, as expected.
Figure 3.3: Predicted survival estimates for death from prostate cancer, given diag-
nosis status after 1 year of randomization, among men who entered the study at age
68. Left figure is for a hypothetical subject who has prostate cancer diagnosed at the
time indicated, while the right one is for a subject not diagnosed at that time.
3.7 Discussion
We have presented a framework to test the screening effect on cancer mortality
with a semiparametric joint model of ordered events. Within the proposed model, the
NPMLE can be obtained by EM algorithm and profile likelihood, and its asymptotic
properties established. Simulation studies indicate good finite sample performance.
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Application of the proposed model to the PLCO prostate cancer data, combined with
simulated SEER control data, reveals the benefit of screening on reducing cancer
mortality.
The model framework is similar to that of Chapter II. It separately specifies
marginal death and conditional incidence given death models. The marginal death
distribution allows us to test the screening effect on the terminal event in an intuitive
way. Regarding the conditional incidence distribution, we extend the beta model in
Chapter II to a semiparametric model based on a multinomial logit model. The tech-
nical difficulty comes from the complexity of the multinomial likelihood function. EM
algorithm can be viewed as a way to replace maximization of the original observed
likelihood by the corresponding complete-data likelihood, which offers computational
advantage and increased stability. With this idea in mind, an artificial latent variable
is introduced to transform the multinomial likelihood to Poisson-type by means of
expectation, and an EM algorithm, treating the artificial variable and censored ob-
servations as missing data, is derived to simplify the maximization step to obtain the
maximum likelihood estimators. Compared with the beta conditional model in Chap-
ter II, this semiparametric model relaxes parametric assumptions and thus provides
wider applicability and increased robustness.
Compared with the model on marginal death, this joint model provides a better
understanding of the natural history of a disease. This carries clinical significance
since the joint model can be used to predict disease prognosis and design optimal
treatments. In addition, it has slight efficiency gain, due to the extra information
from observations with incidence observed, yet death censored. In future work, it
would be of interest to further improve efficiency, by utilizing the strong relationship
between the two events driven by a common cancer progression process.
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CHAPTER IV
A Mechanistic Joint Model to Investigate the
Screening Effect on Cancer Mortality
4.1 Introduction
Prostate-specific-antigen (PSA) testing, a screening tool for prostate cancer, has
been widely used in the United States since the late 1980s. Treatment for prostate
cancer can be confounded by indication provided by the cancer diagnosis that can
occur earlier with PSA screening. While PSA tests led to increased incidence of
cancer diagnosis, their effect on prostate cancer mortality is disputed (Andriole et al.,
2012).
In its natural history, a disease usually progresses through multiple events over
time. Specifically, for cancer studies, there are many events of interest, such as time-
to-diagnosis, time-to-remission, time-to-recurrence, and time-to-death. A joint model
approach is thus needed to capture the relationship between the events driven by a
common cancer progression process.
We focus on two sequential events, time-to-diagnosis and time-to-death. In the
previous two chapters, we evaluated whether screening can benefit cancer mortality,
despite an undoubted effect on cancer diagnosis. In this chapter, we aim to explore
a methodology to provide efficiency gains to test the screening effect. It is critical to
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establish the relationship between cancer diagnosis and death.
Copula modeling has become a popular tool in multivariate analysis of correlated
data since the fundamental work of Clayton (1978). Oakes (1994) and Genest et al.
(1995) proposed the semiparametric two-stage estimation approach. Hsieh et al.
(2008) and Chen (2012) suggested using semiparametric transformation models for
the marginal distributions and a copula model to link them for the joint distribution.
However, due to the dependence between intermediate and terminal events induced
by cancer diagnosis always preceding death, we cannot make the covariate affect one
event while not affecting the other, which excludes the null hypothesis.
Another strategy to formulate the dependence between the events is the condition-
al specification based on modulated point process (Cook and Lawless, 2007; Hu and
Tsodikov, 2013; Rice and Tsodikov, 2017). This strategy describes how the occurrence
of a latent event affects the risk of occurrence of future events in a time-dependent
fashion with a stochastic process frailty. Unlike frailty models which can only handle
positive correlations (Hougaard, 2012), it can accommodate both positive and nega-
tive associations. In addition, this frailty is no longer a random variable, but rather
a stochastic process that jumps from 0 to 1 at the time of the latent event, to ensure
that the subject is not at risk of the future event until the occurrence of the latent
event. This formulation can thus guarantee the ordering of the events.
Figure 4.1 presents the disease progression process we consider, where both inci-
dence of cancer diagnosis and death are observed, yet the type of incidence (causal
to death or not) is missing. Overdiagnosis is caused if non-causal incidence is de-
tected. This mechanism thus incorporates the null hypothesis, where screening does
not affect cancer mortality, although it increases the risk of the incidence event. A
mechanistic joint model is formulated on the partially observed disease progression
process, and a test is developed for the causal effect of screening. We capture the
dependence between events by using a jump process as the frailty. This formula-
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tion results in a strong link and information sharing between cancer incidence and
death, thus providing efficiency gains. Statistical inference is based on nonparametric
maximum likelihood estimation with EM algorithm and profile likelihood.
Figure 4.1: Diagram of cancer progression: Patient is diagnosed with cancer at time
TI and dies at TD, yet the incidence type (incidence 1 or 2) is always missing.
The rest of the chapter is organized as follows. Section 4.2 describes the framework
of our proposed model and derives its essential distributional characteristics. Section
4.3 presents the likelihood in counting process form and the corresponding martin-
gale properties, as well as the estimating procedure for the nonparametric maximum
likelihood estimators. The asymptotic properties are outlined in Section 4.4, with
proofs given in the Appendix C.6. Section 4.5 conducts simulation studies, evalu-
ating the performance of the proposed estimators and hypothesis testing with finite
samples. Section 4.6 analyzes the prostate cancer data. Finally, we discuss the results
in Section 4.7.
4.2 Statistical Framework
4.2.1 Data Structure and Notation
Consider sequential events, such as cancer incidence and death, in our model. Let
TI and TD be the time to incidence and death, respectively; z be a set of fully observed
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covariates; and C be the censoring time which is independent of TI and TD given z.
TI results from two competing incidences: incidence 1 and incidence 2, whose times
to event are T1 and T2, respectively, and are not directly observed. Suppose type of
incidence is never observed. By definition, TI = min(T1, T2). We also assume that of
the two incidences, incidence 1 is causal incidence, while incidence 2 is non-causal,
i.e. only incidence 1 may cause death. Based on this assumption, the unobserved
causal incidence must precede the terminal event: TD ≥ T1 w.p. 1. In addition, we
assume Pr(T1 = TD) = 0.
We observe (XI ,∆I , XD,∆D), where XI = min(TI , C) is the time to the interme-
diate event (i.e. incidence or censoring); XD = min(TD, C) is the time to the terminal
event (i.e. death or censoring); ∆I = 1(XI = TI) is the indicator of observing inci-
dence; and ∆D = 1(XD = TD) is the indicator of observing death.
4.2.2 Model Specification
We formulate our model in two parts. The first is the marginal hazard of incidence:
dΛI(t|z, Tx) = lim
h→0
P (TI ∈ [t, t+ h)|TI ≥ t, z, Tx)
h
= µdHI(t),
here, Tx is the covariate of screening, z represents covariates of interest other than
screening, and they enter the marginal incidence model through µ = exp (βTxTx+ βzz).
Hazard of incidence can be partitioned into two parts, hazard of causal (incidence
1) and non-causal (incidence 2) incidence, dΛ1 and dΛ2, respectively. Suppose the
partition only depends on Tx, for example,
dΛ1
dΛ
= e−γTx. Note that γ should be
between 0 and 1 to guarantee that the proportion of causal incidence falls between 0
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and 1. Then,
dΛ1(t|z, Tx) = lim
h→0




(βTx − γ)Tx+ βzz
]
dHI(t) = µ1dHI(t), (4.1)
dΛ2(t|z, Tx) = lim
h→0
P (T2 ∈ [t, t+ h)|T2 ≥ t, z, Tx)
h
=(1− e−γTx) exp (βTxTx+ βzz) dHI(t) = µ2dHI(t). (4.2)
The second part of the model is the conditional hazard of death given time to
causal incidence dΛD:
dΛD(t|T1, z) = lim
h→0
P (TD ∈ [t, t+ h)|TD ≥ t, T1, z)
h
= 1(t ≥ T1)ηdHD(t), (4.3)







To account for potentially different patterns of disease progression for the time
to incidence and the time to death, separate nonparametrically cumulative baseline
hazard functions HI , HD are used. The cumulative baseline hazard HI(t) summa-
rizes the temporal disease progression pattern leading to an incidence. The other
cumulative baseline hazard HD(t) summarizes the process leading to death. µ1 mod-
els covariate effects on the time to causal incidence T1, µ2 models covariate effects
on the time to non-causal incidence T2, and η models covariate effects on the fail-
ure time TD. Covariate of screening Tx and other covariates of interest z enter the






is the combined vector of
regression coefficients.
The proposed model belongs to a class of stochastic process frailty models, with
unobserved stochastic process 1(t ≥ T1) in (4.3) acting multiplicatively on the baseline
hazard of death. It can also be used to test the screening effect. Specifically, the null
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hypothesis of no benefit of screening on cancer mortality is:




Based on the proposed model hazard functions (4.1), (4.2) and (4.3), the condi-
tional likelihood L0 of observed data, given unobserved time to causal incidence T1,
can be derived as:




−µ2HI(XI)−η[HD(XD)−HD(XI)], T1 = XI
ηµ2dHI(XI)dHD(XD)e
−µ2HI(XI)−η[HD(XD)−HD(t1)], T1 ∈ (XI , XD]
0, otherwise.
(4.4)
2. Subject has incidence at XI , and is censored at XD (i.e. ∆I = 1, ∆D = 0):
L0 =

0, T1 < XI
e−µ2HI(XI)−η[HD(XD)−HD(XI)], T1 = XI
µ2dHI(XI)e
−µ2HI(XI)−η[HD(XD)−HD(t1)], T1 ∈ (XI , XD]
µ2dHI(XI)e
−µ2HI(XI), T1 ∈ (XD,∞).
(4.5)
3. Subject is censored at XI before any event is observed (i.e. ∆I = 0, ∆D = 0):
L0 =

0, T1 ≤ XI




The time to causal incidence T1 is unobserved, and its density function is
f1(t1) = µ1dHI(t1)e
−µ1HI(t1)
The likelihood for a single subject with observed data (XI ,∆I , XD,∆D) can be ob-
tained by taking expectation of the conditional likelihood L0 over T1. The contribu-
tion of each subject to the likelihood falls into one of the following scenarios:















2. Subject has incidence at XI , and is censored at XD (i.e. ∆I = 1, ∆D = 0):
















3. Subject is censored at XI before any event is observed (i.e. ∆I = 0, ∆D = 0):
L00 = S1(XI)S2(XI) = e
−(µ1+µ2)HI(XI) (4.9)
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Combining (4.7), (4.8) and (4.9), the contribution of subject i to the observed
data likelihood is:
Li = ∆I∆DL11,i + ∆I(1−∆D)L10,i + (1−∆I)L00,i (4.10)
4.2.5 Conditional Distribution of Time to Causal Incidence
The model also allows us to make predictions of the distribution of time to causal
incidence, given observed data and estimates of η, µ1, µ2, {dHI} and {dHD}. This is
of particular interest to clinical practice, as it allows us to examine, for a subject who
has not experienced the terminal event after some specified time, the distribution of
the time to the causal incidence. Specifically, the survival functions can be written
as (see Appendix C.2 for details):
1. Consider a subject whose incidence and death are both observed,
ST1(t1|XI , XD) =










, t1 ∈ [XI , XD]
0, t1 > XD.
2. Consider a subject whose incidence is observed, yet terminal event censored,
• If t1 < XI ,
ST1(t1|XI , XD) = 1.
























3. Consider a subject with no events observed,
ST1(t1|XI , XD) =

1, t1 < XI
e−µ1[HI(t1)−HI(XI)], t1 ≥ XI .
4.3 Nonparametric Maximum Likelihood Estimation
The proposed model is semiparametric, consisting of a parametric component β
for covariate effects and nonparametric components HI(·), HD(·) for baseline haz-
ards. HI and HD are non-decreasing step functions with jumps {dHI} and {dHD}
only at the observed event (incidence/death) times. Let us denote the full parameter
set Ω = (β, {dHI}, {dHD}). We use the EM algorithm (Tsodikov (2003)) and pro-
file likelihood approach to obtain the nonparametric maximum likelihood estimator
(NPMLE) for Ω.
4.3.1 Martingale Theory
In counting process notation, for subject i, let NIi(t) = 1(XIi ≤ t,∆Ii = 1) and
YIi(t) = 1(XIi ≥ t) be the observed counting process and at risk process for incidence,
respectively; let NDi(t) = 1(XDi ≤ t,∆Di = 1) and YDi(t) = 1(XDi ≥ t) denote the
observed counting process and at risk process for death.
We can define the following martingales, based on observed counting processes
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with respect to filtration Fi(t−) = σ
{
NIi(x), NDi(x), YIi(x), YDi(x), zi : x ∈ [0, t)
}
,






dMDi(t) = dNDi(t)− YDi(t)dΛDi(t; tI)
= dNDi(t)− YDi(t)ΘDi
(








= µ1 + µ2,
ΘDi
(












dΛIi(t) is the hazard of subject i having incidence at time t, and dΛDi(t; tI) is the
hazard of dying of cancer at time t, given incidence at time tI . Note H∗(t) denotes the






t; tI , β,HI(t), HD(t)
)
to ΘIi(t) and ΘDi(t; tI), respectively, in the rest of
this paper. They can be derived through the following probabilistic argument (see
Appendix C.3 for more details):
E{dNIi(t)|Fi(t−)} = YIi(t)Pr
(
dNIi(t) = 1|YIi(t) = 1
)
= YIi(t)ΘIi(t)dHI(t),
and E{dNDi(t)|Fi(t−)} = YDi(t)Pr
(





Define partial derivatives of ΘIi and ΘDi, with respect to {dHI(s)}, {dHD(s)},














































As in Hu and Tsodikov (2013), for a functional J(f), f = f(x), the functional









We can rewrite the log-likelihood of subject i in counting process form:















Here, τ is the duration of the study. Using lIi and lDi to denote the quantities in















(lIi + lDi) = lI + lD.
It is easy to see that lI corresponds to the likelihood contributions from incidence,
and lD corresponds to the contributions from the subsequent time segments between
incidence and death.
Applying the functional derivative to the full log-likelihood, with respect to the
infinite-dimensional parameters {dHI(s)} and {dHD(s)}, we can obtain the score





























which are both martingales under the true model.
Taking derivative of the log-likelihood, with respect to the regression parameter















which is also a martingale under the true model.
Set equations (4.12), (4.13), and (4.14) to zero, and solve them, can give the
NPMLE Ω̂ = (β̂, {dĤI}, {dĤD}).
4.3.3 Nonparametric Maximum Likelihood Estimator
The NPMLE can be obtained using




However, it is unpleasant to directly maximize, since the nonparametric parts {dHI}
and {dHD} are of infinite-dimension. Instead, we apply the profile likelihood to
estimate β, {dHI} and {dHD} jointly. We first obtain the estimators of {dHI}
and {dHD} with fixed β. Then replacing {dHI , dHD} in the observed log-likelihood





. Finally, the finite-dimensional parameter β is estimated
by maximizing the resulting profile likelihood over β.
The key step is to obtain the estimator of {dHI} and {dHD}, given β. In our
model, since type of incidence is always unobserved, and in view of the simplicity of
complete-data problem, we use EM algorithm to estimate the baseline hazards. For
the implementation of EM, E-step is to impute the missing data, and M-step is to
maximize the complete-data likelihood with imputed data plugged in. Derivation of
EM algorithm for our model is shown in Appendix C.5. It gives us the score functions






























−ΨD(s) = 0, (4.16)
where
ΨI(s) = YI(s)(µ1 + µ2)
+∆IYD(s)[1− YI(s)]µ1µ2
µ1V (s
−, XD)−W (s) + (1−∆D)W (XD)
µ1W (XI) + µ1µ2V (XI , XD) + (1−∆D)µ2W (XD)
,
θI(s) = (1−∆I)[1− YD(s)]µ1eµ1HI(XI)−µ1HI(s)
+ ∆Iµ1µ2
YD(s)[1− YI(s)]W (s) + [1− YD(s)](1−∆D)eηHD(XD)−µ1HI(s)
µ1W (XI) + µ1µ2V (XI , XD) + (1−∆D)µ2W (XD)
,
ΨD(s) = ∆IYD(s)[1− YI(s)]ηµ1
W (XI) + µ2V (XI , s
−)








W (s) = eηHD(s)−µ1HI(s).


































Equations (4.17) and (4.18) solve for dHI(s) and dHD(s) iteratively, k = 0, 1, 2, ...,








D . Note, at convergence,
the last term in equation (4.15) disappears, and the estimating equation is the same
as that obtained from observed data; equation (4.16) also takes the same form as
the score function for dHD(s) from observed data. Estimators at convergence are
consistent (Tsodikov (2003)).
The estimation procedure is described as follows:
Start with β(0) = 0, j = 0.
1. Maximize the likelihood over HI(β) and HD(β), respectively, given β = β
(j):
(a) Set k = 0. Initialize d̂H
(0)
I (s) and d̂H
(0)
D (s) such that all jumps in the
baseline hazards have equal size, respectively.
(b) With β fixed, calculate dĤ
(k+1)
I (s) and dĤ
(k+1)
D (s) using equations (4.17)
and (4.18).
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(c) Repeat step (b) to update dĤ
(k+1)
I (s) and dĤ
(k+1)
D (s), until convergence
∥∥dĤ(k+1)I (s)− dĤ(k)I (s)∥∥2 < ε and ∥∥dĤ(k+1)D (s)− dĤ(k)D (s)∥∥2 < ε.
2. Maximize the profile log-likelihood lpr(β) = l(β, {dĤI(β)}, {dĤD(β)}) over β:
(a) Calculate profile log-likelihood l(β, {dĤI(β)}, {dĤD(β)}) using equation
(4.10).
(b) Find β(j+1) by maximizing lpr(β) over β: β
(j+1) = argmaxβ lpr(β), us-
ing conventional optimization method, e.g. Broyden-Fletcher-Goldfarb-
Shanno algorithm (BFGS).
Iteratively apply steps 1-2 to estimate β, until convergence of lpr(β)
lpr(β
(j+1))− lpr(β(j)) < ξ.
Note the convergence tolerance for the inner loop (EM algorithm used to estimate
baseline hazards, given β) should be stricter than that for the outer loop, e.g. ε =
10−6, ξ = 10−5.
4.4 Asymptotic Properties
We apply the empirical process (Kosorok, 2008; Van Der Vaart and Wellner, 2000)
and the theory of martingale structure in counting process to build the asymptotic
properties, adapted from previous work (Zeng and Lin, 2007, 2010; Chen, 2009, 2010;
Hu and Tsodikov, 2014; Rice and Tsodikov, 2017).
Assuming regularity conditions hold, in the following, Theorem IV.1 and Theo-
rem IV.2 state the consistency and weak convergence results of the NPMLE Ω̂ =
(β̂, {dĤI}, {dĤD}), while Theorem IV.3 justifies the use of negative Hessian matrix
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from profile log-likelihood in variance estimation. Regularity conditions and proofs
are provided in Appendix C.6.
Under regularity conditions,
Theorem IV.1. With probability 1: β̂ converges to β0; Ĥ(t) = (ĤI(t), ĤD(t)) con-
verges to H0(t) = (H0I (t), H
0
D(t)) uniformly over the interval [0, τ ], respectively. Here,
β0, H0I (t) and H
0





converges weakly to a zero-mean Gaussian
process. In addition, consider a linear functional of Ω̂,
n1/2
{













where a is a real vector, b1(t) and b2(t) are functions with bounded total variation in
[0, τ ], evaluated at the observed incidence and death times, respectively. Let ΦT =
(aT , {b1(·)}T , {b2(·)}T ). The asymptotic variance-covariance function of the linear
functional above can be consistently estimated by ΦT (In)−1Φ, where In is the observed










subject i’s observed log-likelihood defined as equation (4.11).
Theorem IV.3. The inverse of the negative Hessian matrix of the profile log-likelihood
with respect to β is a consistent estimator of the limiting variance-covariance matrix



























This section performs Monte Carlo simulations to assess the proposed method-
ology. The simulation settings were as follows. The baseline cumulative hazard
for incidence was HI(t) = 0.5t
2, and the baseline cumulative hazard for death was
HD(t) = t. We considered two covariates Tx and Z1, where Tx∼Bernoulli(0.5), and




= e−β3Tx. The intensity of the incidence event was µ = eβ1z1+β2Tx,
while the intensity of the terminal event was η = eβ4z1+β5Tx. The true parameters
were (β1, β2, β3, β4, β5) = (−0.5, 1, 0.8,−1, 0.5). Censoring was simulated from the ex-
ponential distribution Exp(0.3), yielding 20% intermediate and 40% terminal events
censored.
4.5.1 Finite-sample Properties of Parameter Estimates
We conducted simulations to study the finite-sample properties of the parameter
estimates obtained. Samples of size 500 and 1000 were examined, each with 1000
replicates. Standard errors were obtained from the numerically evaluated Hessian
matrix at the solution.
The simulation results are summarized in Table 4.1. The proposed estimators
perform well with diminishing bias as sample size increases. The asymptotic standard
errors are close to the empirical standard deviations, validating the performance of the
variance estimators. The 95% coverage probabilities for all the estimators approach
the 95% nominal level for both sample sizes. Note that the estimators of β3 and
β5 slightly underperform in terms of bias, variance estimation and 95% coverage
probability. This is as expected, due to the missingness of the incidence type.
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Table 4.1: Simulation results using the proposed mechanistic joint model.
N β Truth Bias ASE ESD 95% CP
500
β1 -0.5 0.002 0.071 0.072 0.954
β2 1 0.003 0.077 0.076 0.963
β3 0.8 -0.153 0.204 0.204 0.912
β4 -1 0.001 0.099 0.097 0.949
β5 0.5 -0.091 0.141 0.146 0.877
1000
β1 -0.5 0.000 0.048 0.050 0.964
β2 1 0.007 0.053 0.054 0.957
β3 0.8 -0.092 0.131 0.139 0.935
β4 -1 0.003 0.069 0.069 0.947
β5 0.5 -0.056 0.101 0.106 0.910
ASE: average of estimated standard errors
ESD: empirical standard deviation based on Monte Carlo estimates
95% CP: 95% coverage probability
4.5.2 Hypothesis Testing
Given the proposed estimators, we constructed the likelihood ratio test (LRT) to
test the covariate effect on the terminal event. The simulation set-up was the same as
before. In our scenario, the null hypothesis of no benefit of treatment on the marginal
terminal event was:
H0 : β2 = β3, β5 = 0.
Sample size was chosen to be 1000. The simulation procedure was as follows:
1. Generate a data set under H0.
2. Fit the models with and without the restriction, respectively, and obtain the
two log-likelihoods.
3. Calculate the LRT statistic, and decide if H0 is rejected.
4. Repeat steps 1-3 2000 times, and calculate the empirical p-value.
Based on the simulations, the 0.05 significance level is well maintained (0.051).
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4.6 Application to Prostate Cancer Screening Trial Data
4.6.1 Data
The proposed method was applied to the motivating setting of the prostate cancer
screening trial, testing the screening effect on cancer mortality. The data come from
the PLCO trial, with patients entering the trial aged 55-74 years old. The control arm
in the PLCO trial was contaminated (Vickers, 2017), as about 50% of PLCO control
patients had PSA testing before enrollment, and of the remainder, close to 90% had
PSA measured during the trial (Shoag et al., 2016). Thus, we needed to introduce a
set of uncontaminated control data from external data to assess the screening effect.
Comparing SEER with PLCO data (Pinsky et al., 2012), there was no unambiguous
evidence showing a healthy volunteer effect. Therefore, a simulated subset of SEER
data, with diagnosis between 1980 and 1987 before the use of PSA as a screening
tool, was created to act as uncontaminated “perfect” controls.
In the combined data set, 76,674 subjects are from PLCO trial (38,335 subjects
in the screening arm, and 38,339 subjects in the control arm), and 38,335 subjects
are from the SEER control arm. For patients from the PLCO trial, 4418 (11.52%) in
the screening arm were diagnosed with prostate cancer, and 145 (0.38%) died of it;
while 4036 (10.53%) in the control arm were diagnosed and 142 (0.37%) died of it.
For patients in the simulated SEER control arm, 2726 (7.11%) were diagnosed with
prostate cancer, and 606 (1.58%) died of it. Maximum follow-up time was 13 years.
From the data, we have information about time-to-diagnosis and time-to-death. In
addition to arm (screening/control) and trial (PLCO/SEER), we are also interested
in studying the age effect, since age is an important risk factor for prostate cancer.
To make patients from different trials comparable, the simulated SEER data have the
same age distribution as the PLCO data.
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4.6.2 Results
In our proposed method, covariates entered the model via
µ1 = e
β1Age+(β2−β4)Arm+(β3−β5)Trial
µ2 = (1− e−β4Arm+β5Trial)eβ1Age+β2Arm+β3Trial
η = eβ6Age+β7Arm+β8Trial
The goodness of fit for the Cox regression model for marginal incidence was
checked. The proportional hazards assumptions for the covariates age, arm and trial
are supported, with all the three single goodness of fit p-values <0.0001. Table 4.2
shows the regression coefficient estimates for the proposed joint model. Based on
the analysis of cancer diagnosis incidence, older patients have greater risk of cancer
detection (β1=0.22, HR=1.69, p-value<0.0001), and screening quickens the time-to-
diagnosis (PLCO screening vs. PLCO control: β2=0.10, HR=1.11, p-value<0.0001;
PLCO control vs. SEER control: β3=0.64, HR=1.90, p-value<0.0001). The big d-
ifference between β2 and β3 may be due to the contamination of the PLCO control
arm, since β2 is the log hazard ratio of comparing “systematic versus opportunistic
screening” (Vickers, 2017), while β3 is the log hazard ratio of comparing opportunistic
screening versus control.
Regarding the analysis of cancer mortality given causal incidence, the risk of dy-
ing from prostate cancer significantly increases for older patients (β6=0.19, HR=1.21,
p-value<0.0001). The negative signs of β7 and β8 indicate that given the same occur-
rence of causal incidence, patients in the screening arm have a larger gap time and
better survival than those in the control arm. This can be at least partly explained
by the fact that with the same time of causal incidence, the screening patients tend
to have better health conditions than the control patients, thus lower risk of death,
even under H0 (no benefit of screening on mortality). Yet it is difficult to separate
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and interpret the screening effect from β7 and β8 directly.
Table 4.2: Prostate cancer screening trial analysis results.




β1 0.224 0.009 <0.0001
β2 (PLCO scr vs. PLCO control) 0.102 0.022 <0.0001
β3 (PLCO control vs. SEER control) 0.642 0.025 <0.0001
β4 0.008 1.561 0.996




β6 0.188 0.036 <0.0001
β7 (PLCO scr vs. PLCO control) -0.159 1.578 0.920
β8 (PLCO control vs. SEER control) -1.541 1.385 0.266
The proposed model can be adopted to test the screening benefit. With this model
specification, the null hypothesis of no benefit of screening on cancer mortality is
H0 : β2 = β4, β3 = β5, β7 = β8 = 0
Both the full model and the reduced model under H0 were fitted to conduct the
likelihood ratio test. The test statistic is 361.2  Chi-squared statistic with 4 df at
level 0.05 = 9.488. Thus, we can reject H0, and conclude that screening does affect
cancer mortality.
To assess model fit (Dejardin et al., 2010), Figure 4.2 and 4.3 present the survival
estimates for time-to-diagnosis and time-to-death, respectively, for subjects who en-
tered the study at age 62, stratified by arm and trial. Both of the figures have plots of
marginal survival functions obtained using the proposed model, which closely match
the KM estimates obtained from the observed data, indicating that our proposed
model works well to describe and fit the data.
4.7 Discussion
We have presented a framework to test the screening effect on cancer mortality
with a mechanistic joint model of ordered events. Within the proposed model, the
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Figure 4.2: Survival estimates for time-to-diagnosis for subjects who entered the
study at age 62. Proposed model (dotted lines) closely matches Kaplan-Meier (KM)
estimates (solid lines).
Figure 4.3: Survival estimates for time-to-death for subjects who entered the study at
age 62. Proposed model (dotted lines) closely matches Kaplan-Meier (KM) estimates
(solid lines).
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NPMLE can be obtained by EM algorithm and profile likelihood, and its asymptotic
properties established. Simulation studies indicate good finite-sample performance.
Application of the proposed model to the PLCO prostate cancer data, combined with
simulated SEER control data, reveals the benefit of screening on reducing cancer
mortality.
The traditional joint models usually let an effect on the diagnosis propagate
through the dependence structure to the terminal event, thus excluding the null
hypothesis. In our formulation, we consider a partially observed disease progression
process where overdiagnosis may be caused. This mechanism incorporates the null
hypothesis, where screening does not affect cancer mortality, although it increases the
risk of the incidence event.
Compared with the models in Chapter II and III, the proposed model can provide
efficiency gains. We sampled a subset of data with 10,000 observations from the
prostate cancer screening trial data, and conducted the LRT using both the model
in Chapter II and the proposed mechanistic model. Both tests show significance, yet
the p-value from the Chapter II model (p-value = 1.41×10−6) is twice as big as from
the mechanistic model (p-value = 7.00 × 10−7). The mechanistic model recognizes
a common cancer progression process driving incidence and mortality, thus sharing
information and building a strong link between the events if the mechanism assumed
is true. However, if we are uncertain about the mechanism, models in the previous
chapters are more robust and may be safer choices. In other words, it is critical to




This dissertation presents three different semiparametric joint models to test the
screening effect on cancer mortality. All three models show screening benefit of pro-
longing cancer survival with the joint analysis of prostate cancer screening trial and
population registry data. Models in Chapter II and III are under the same frame-
work of conditional modeling approach, except the conditional incidence model is
parametric in Chapter II and extended with a semiparametric form in Chapter III ;
while Chapter IV proposes a mechanistic model with a latent structure. Comparing
the three models, the previous two models are more robust with respect to violation-
s of the mechanistic assumptions; the mechanistic model provides a more realistic
description of a common cancer progression process driving incidence and mortali-
ty. It captures the most plausible dependence structure between the two events and
endows the model parameters with a biological meaning in terms of a causal and a
non-causal intermediate events. In addition, due to its latent structure, even if re-
stricted for identifiability, the mechanistic model has more degrees of freedom, thus
is more flexible. Despite the model complexity, it is more efficient when testing the
null hypothesis of no screening benefit.
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The current work may be extended in several directions:
• Evaluate the relative contribution of treatment advances over calendar time.
In real data analysis, we use the PLCO trial of prostate cancer, combined with
a simulated subset of SEER data with diagnosis between 1980 and 1987. In the
PLCO trial, prostate cancer can be detected between 1993 and 2009, which is
different from screening naive simulated SEER data before 1988. When evalu-
ating the screening effect comparing the PLCO trial with population data, it is
important to separate the effect of screening from the effect of the new treat-
ments in later years. The question of whether new treatment contributes to
better prostate cancer survival may call for additional modeling efforts. Mor-
tality can be regressed on some surrogate of screening intensity, such as the
mean lead time in the population. Model is fit to the 1993-2009 period of
SEER data when new treatments are operating. Then a model prediction with
zero lead time is calculated that gives the back extrapolated predicted mortali-
ty with new treatments but without screening. Comparing this prediction with
observed pre-1988 mortality gives an idea of how much progress in treatment
contributed to the estimated effect.
• More complex observed terminal event.
The observed terminal event may be more complicated with several causes of
death, which can potentially be related to prostate cancer. Inverse probability
of censoring weighting or joint frailty modeling can be introduced to deal with
this dependent censoring.
• Optimal treatment regimes.
Consider the situation with observed endpoints of cancer recurrence and death.
Initial primary treatment may affect the timing of recurrence, and also the
effectiveness of recurrence treatment. Our framework in this dissertation may
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be adopted to study the optimal treatment regimes in a difficult situation where
a more aggressive primary treatment improves the time to recurrence, but makes
the salvage treatment less effective. This problem calls for the development of





Conditional Modeling of Incidence of Cancer
Diagnosis on Terminal Event
A.1 Prediction of survival function for the terminal event
This section presents the derivation of conditional survival functions of terminal
event given incidence information at time t∗ and estimates of β and {dH}. Specifically,
we are interested in Pr(TD > t|TI ,∆1).
• If t ≥ t∗,
1. Consider a subject that has been diagnosed at t∗, i.e. ∆1 = 1
Pr(TD > t|TI = t∗) =
Pr(TI = t










∗|tD) dtD + fTD(τ)fTI |TD(t∗|τ)∫ tlf
t∗
fTD(tD)fTI |TD(t



































2. Consider a subject that has not been diagnosed at t∗, i.e. ∆1 = 0
Pr(TD > t|TI > t∗) =
Pr(TI > t











fTD(tD)fTI |TD(tI |tD) dtIdtD +
∫ τ
t∗




fTD(tD)fTI |TD(tI |tD) dtIdtD +
∫ τ
t∗
fTD(τ)fTI |TD(tI |τ) dtI














































































• If t < t∗,
Since death must happen after incidence,
Pr(TD > t|TI ,∆1) = 1.
A.2 Derivation of hazard terms
For ease of notation, we suppress the subscript i for each individual subject.
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1. The hazard of having incidence at time t:
dΛ1(t) = Pr
(









































































2. The hazard of dying from cancer at time t, given incidence at time t1:
dΛ2(t|t1) = Pr[dN2(t|t1) = 1|Y2(t|t1) = 1] =
Pr(TI = t1, TD = t)




Here, the numerator is














































































Taking derivatives of l, with respect to β and dH(s), respectively, we can obtain
the corresponding score functions. Since l = l1 + l2, score function U = U1 + U2.



























































































{∂ log dΛ2i(t; t1)
∂(·)
dN2i(t)− Y2i(t)dΛ2i(t; t1)






































































































Finally, since U(·) = U1,(·) + U2,(·), score functions for dH(s) and β, respectively,









































In our model, when the terminal event is censored, time-to-terminal TD is missing,
and EM algorithm can be adopted to estimate the baseline hazards (Tsodikov, 2003).








Here, L0 is the conditional likelihood of the incidence event, given the terminal event
observed at TD = tD; and P0 is the likelihood of the time-to-terminal TD.
In the (k+1)th iteration,
E-step: Unconditional score function









M-step: Set U(s) = 0, then we can obtain dH(k+1)(s) to update the expression of
dH(s).
The rest of this section is organized as follows. First, we derive the E step for {dH}
for the three different cases respectively (both events observed, incidence observed yet
death censored, and neither events observed). Then we derive the M step to maximize
the likelihood with respect to {dH}, which has a closed-form expression analogous




































































The unconditional score functions are







In the rest of EM algorithm section, we keep iteration index for (k + 1)th iteration




is just observed data likelihood, as in Section 2.2.3.
1. Subject has incidence at X1, and dies at X2 (i.e. ∆1 = 1, ∆2 = 1):
Since TD is not missing in this case,




2. Subject has incidence at X1, and is censored at X2 (i.e. ∆1 = 1, ∆2 = 0):
The complete and observed data likelihoods differ in the two cases X2 ≤ tlf and
X2 > tlf , thus we will consider them separately.
(a) If X2 > tlf :
In this case, TD = τ , the complete data likelihood can be written as













Since there is no missingness in the complete data,
UdH(s) = U0,dH(s) = −ηYlf (s).
(b) If X2 ≤ tlf :
First, we write out Lcom from L0 and P0. Next we derive the conditional
score function U0,dH(s) for the baseline hazard, and finally obtain the un-
conditional score function UdH(s).




−ηH(tD), tD ≤ tlf ,
e−ηH(tlf ), tD = τ.
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The conditional likelihood of the incidence, given TD = tD is
L0 =

fTI |TD(X1|tD), tD ∈ (X2, tlf ],
fTI |TD(X1|τ), tD = τ,
0, tD ≤ X2.



























e−ηH(tlf ), tD = τ.






− η1(TD ≥ s), TD ∈ (X2, tlf ]
−η1(tlf ≥ s), TD = τ.
Since U0,dH(s) depends on s, we consider the calculation of the uncondi-
tional score function UdH(s) in three cases, s ≤ X2, X2 < s ≤ tlf , and
s > tlf , respectively.
• s ≤ X2, i.e. Y2(s) = 1
To calculate UdH(s), first we have U0,dH(s) = −η.
Since U0,dH(s) does not depend on the missing variable,





• X2 < s ≤ tlf , i.e. Y2(s) = 0, Ylf (s) = 1
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− η1(TD ≥ s), TD ∈ (X2, tlf ],
−η, TD = τ.
Then the numerator
E[U0,dH(s)L0] =
E[1(TD = s)1(X2 < TD ≤ tlf )L0]
dH(k+1)(s)
− ηE[1(TD ≥ s)1(X2 < TD ≤ tlf )L0]− ηE[1(TD = τ)L0].
We can derive the term E[1(TD = s)1(X2 < TD ≤ tlf )L0] as














The term E[1(TD ≥ s)1(X2 < TD ≤ tlf )L0] can be derived as

















The term E[1(TD = τ)L0] can be derived as












ηe−ηH(tlf ) = V.

















Note the denominator E[L
(k)
0 ] is the observed likelihood L10, which can














ηU(s−, tlf ) + ηV − U.s
]
U(X2, tlf ) + V
.
• s > tlf , i.e. Ylf (s) = 0
Since U0,dH(s) = 0, the unconditional score function is also zero.
Combining these results, the contribution of a subject, with intermediate event
observed at X1 yet terminal event censored at X2, to the unconditional score
functions, when s ≤ tlf , can be written as














)ηU(s−, tlf ) + ηV − U.s
U(X2, tlf ) + V
]}
− 1(X2 > tlf )η. (A.2)
Note, UdH(s) = 0 when s > tlf , indicating that there is NO jump in {dH(s)}
when s > tlf .
3. Subject is censored at X2 before any event is observed (i.e. ∆1 = 0, ∆2 = 0):
We now proceed through the same steps as for the case ∆1 = 1, ∆2 = 0.
(a) If X2 > tlf :
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There is no missingness for the complete data, thus
UdH(s) = U0,dH(s) = −ηYlf (s).
(b) If X2 ≤ tlf :






fTI |TD(tI |tD)dtI , tD ∈ (X2, tlf ],∫ τ
X2
fTI |TD(tI |τ)dtI , tD = τ,
0, tD ≤ X2.





























dtI , tD = τ.






− η1(TD ≥ s), TD ∈ (X2, tlf ]
−η1(tlf ≥ s), TD = τ.
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Next, we calculate UdH(s) in three cases, s ≤ X2, X2 < s ≤ tlf , and
s > tlf , respectively.
• s ≤ X2, i.e. Y2(s) = 1
To calculate UdH(s), first we have U0,dH(s) = −η.
U0,dH(s) does not depend on the missing variable, then





• X2 < s ≤ tlf , i.e. Y2(s) = 0, Ylf (s) = 1





− η1(TD ≥ s), TD ∈ (X2, tlf ],
−η, TD = τ.
Then the numerator
E[U0,dH(s)L0] =
E[1(TD = s)1(X2 < TD ≤ tlf )L0]
dH(k+1)(s)
− ηE[1(TD ≥ s)1(X2 < TD ≤ tlf )L0]− ηE[1(TD = τ)L0].
We can derive the term E[1(TD = s)1(X2 < TD ≤ tlf )L0] as
















The term E[1(TD ≥ s)1(X2 < TD ≤ tlf )L0] can be derived as


















=W (s−, tlf ).





























ηW (s−, tlf ) + ηZ −W.s
]
.
Note the denominator E[L
(k)
0 ] is the observed likelihood L00, which
can be rewritten as W (X2, tlf ) + Z. Thus, the unconditional score













ηW (s−, tlf ) + ηZ −W.s
]
W (X2, tlf ) + Z
.
• s > tlf , i.e. Ylf (s) = 0
Since U0,dH(s) = 0, the unconditional score function is also zero.
Combining these results, the contribution of a subject, censored at X2 before
any event is observed, to the unconditional score functions, when s ≤ tlf , can
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be written as














)ηW (s−, tlf ) + ηZ − U.s
W (X2, tlf ) + Z
]}
− 1(X2 > tlf )η. (A.3)
Note, UdH(s) = 0 when s > tlf , indicating that there is NO jump in {dH(s)}
when s > tlf .













Ψ(s) = 1(X2 ≤ tlf )
{
Y2(s)η + [1− Y2(s)](1−∆2)
[
∆1
ηU(s−, tlf ) + ηV − U.s
U(X2, tlf ) + V
+ (1−∆1)
ηW (s−, tlf ) + ηZ −W.s
W (X2, tlf ) + Z
]}
+ 1(X2 > tlf )η,




U(X2, tlf ) + V
+(1−∆1)
W.s




Suppose we have n independent subjects with observed data (X1i,∆1i, X2i,∆2i),






































The above equation solves for dH(s) iteratively until convergence, and the estimator
at convergence, d̂H(s), is a consistent estimator of dH(s) (Tsodikov (2003)).
A.5 Asymptotic properties
This section presents the technical details of the asymptotic properties of the
NPMLE Ω̂ = (β̂, {dĤ}), adapted from Hu and Tsodikov (2014), Supplementary
Materials C and Rice and Tsodikov (2017), Appendix F. To establish the asymptotic
properties, we assume the following conditions are satisfied (Fleming and Harrington
(2011), p289-p290):
1. The true values of baseline hazards H0 are strictly increasing and differentiable.
The true parameter set Ω0 is in the interior of the compact convex set H.
2. With probability 1, P [Y2(t)|z] > 0, P [∆2 = 0, X2 = τ |z] > 0. The at risk set
will not shrink to zero.
3. The Hessian matrix In evaluated at the true value Ω0 = (β0, {dH0}) is positive
definite, and converges in probability to a deterministic and invertible operator
I0.
4. The model is identifiable such that
{Λ} = {Λ0} uniformly over Ω ⇒ Ω = Ω0.
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A.5.1 Proof of Theorem II.1
To prove consistency: |Ω̂−Ω0| p−→ 0, based on Theorom 2.12 of Kosorok (2008),
in addition to the regularity conditions provided above, another three conditions need
to be verified:
(a) ln(Ω̂n) = supΩ∈H ln(Ω)− op(1)
(b) Identifiability condition 2: For any sequence Ωn ∈ H,
lim infn→∞l(Ωn) ≥ l(Ω0) ⇒ ‖Ωn − Ω0‖
p−→ 0.
(c) Uniform convergence condition: supΩ∈H |ln(Ω)− l(Ω)|
p−→ 0.
Note, Ω̂n here is the maximum likelihood estimator of Ω, which is Ω̂ in our previous
notation.
We verify the three conditions as follows:
1. To verify condition (a), Ω̂n is the maximum estimator of Ω, thus condition (a)
is satisfied.
2. To verify condition (b), by Lemma 14.3 of Kosorok (2008), we just need to prove
that l(Ω) is upper semicontinuous with a unique maximum at Ω0.
The model is characterized by defining the hazard functions of dΛ1(t) and
dΛ2(t), which are both functions of Ω. Let F1(t) and F2(t) be the cumula-
tive density functions for incidence and death, subject to censoring; and let
S1(t) and S2(t) be the survival functions for observed incidence and death.






2(t) denote the corresponding true functions. Note
that dF1(t) = S1(t)dΛ1(t) and dF2(t) = S2(t)dΛ2(t). The true log-likelihood
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1 (t)− S01(t)dΛ1(t) + log dΛ2(t)dF 02 (t)− S02(t)dΛ2(t)
}
,
where the expectation is taken over covariate z.






dF 01 (t)[log dΛ1(t)− log dΛ01(t)]− S01(t)[dΛ1(t)− dΛ01(t)]




dF 0(t)[log dΛ(t)− log dΛ0(t)]− S0(t)[dΛ(t)− dΛ0(t)]

























































where ρ(x) = log x − x + 1 is a non-positive convex function, with a unique






= 1, i.e., dΛ1(t) = dΛ
0




Given regularity condition 4, under the identifiable model, D has a unique
maximum at Ω0. Since maximizing D is equivalent to maximizing l(Ω), we can
conclude that l(Ω) has a unique maximum at Ω0. We also know l(Ω) is upper
semicontinuous, thus condition (b) holds.
3. To verify condition (c), given regularity condition 1, Ω is in the class of functions
of bounded variation with integrable envelope, so H(t) is bounded. Therefore,
H is a Glivenko-Cantelli class. Then, since the functionals Λ and l(Ω) are
continuous, and the envelope function is integrable, then by the preservation of
Glivenko-Cantelli theorem (Van Der Vaart and Wellner (2000)), the integrand
in l(Ω) is also Glivenko-Cantelli. Therefore, we apply the uniform law of large





A.5.2 Martingale Representation of Score Functions
In this part, we justify that the score functions for H(t) and β are all martingales
under the true model.
We first consider the score function UH(x). Based on score function (2.7), we
integrate the expression over dH(s), normalize it by 1/n, and obtain the normalized




















































H(x ∧ t)dM2i(t; t1)
}
.
Similar as the proof in (Hu and Tsodikov (2014), Supplementary Materials B),
Let ε1(t, x) =
Θ̇1i,dH(s)(t)
Θ1i(t)
H(x ∧ t), ε2(t, x) =
Θ̇2i,dH(s)(t;t1)
Θ2i(t;t1)





















Consider the increment of UH(x) over x,






































The first term is 0, based on the martingale property of M2(x). ε1(t, x) depends on t
when t < x, so
∂ε1(t, x)
∂x
= 0 when t < x. E[dM1(t)|F(x−)] = 0, if t ≥ x−, based on
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= 0. Thus, E[dUH(x)|F(x−)] = 0,
and UH(x) is a martingale under the true model.






























are both predictable, so Uβ, which is the linear trans-
formation of these two terms, is also a martingale under the true model.
A.5.3 Proof of Theorem II.2
We prove Theorem II.2 in two steps. Suppose U(Ω) = (Uβ, UH(t))
T is the set
of score functions for parameter set Ω. First, we prove the weak convergence of the
score functions at the true parameter n1/2U(Ω0) by Martingale Central Limit Theorem
(MCLT). Then, we seek for the relationship between n1/2(Ω̂−Ω0) and n1/2U(Ω0), to
obtain the weak convergence of the NPMLE Ω̂.
Based on the martingale representation of U(Ω0) in Appendix A.5.2, and the fact
that N1i and N2i, i = 1, 2, ..., n, are orthogonal, it follows that n
1/2U(Ω0) converges
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weakly to a zero-mean Gaussian process with its variance-covariance function char-
acterized by σ2β(Ω
0), σ2H(x, y; Ω
0) and σ2β,H(x)(x; Ω
0) as derived below.




















































P (T2 ≥ t)dH(t).
















P (T2 ≥ t)dH(t).
Similarly, as n→∞,












1(t ≤ x)1(t ≤ y) + ε2(t, x)ε2(t, y)
]
P (T2 ≥ t)Θ2(t; t1)dH(t),



















1(t ≤ x) + ε2(t, x)
]
Θ̇2,β(t; t1)P (T2 ≥ t)dH(t).











. Define a linear information operator I∞ as



















I∞(t, s)Ωs = −














With Taylor expansion, expand U(Ω̂) at the true parameter Ω0, we have
U(Ω̂) = 0 = U(Ω0)− I∞(t, s)(Ω̂− Ω0) + op(1)
⇒ I∞(t, s)n1/2(Ω̂− Ω0) = n1/2U(Ω0) + op(1). (A.4)
Assume that the Fredholm operator expressed by the kernel I∞ of the Fredholm
integral equations (A.4) of the first kind is square integrable, and the equation I∞Ω =
0 has only the trivial solution Ω = 0. Then based on Theorem 3.3.1 of Vaart and
Wellner (1996), equations (A.4) has the unique solution, and there exists the inverse
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information operator I−1∞ (t, s) such that
n1/2(Ω̂− Ω0) = I−1∞ (t, s)n1/2U(Ω0) + op(1).
Take differentiation of the equation E[U(Ω0)] = 0 with respect to Ω at the true
parameter Ω0, we have the equivalence between I∞ represented by the log-likelihood
second derivative, and
I∞(t, s) =












which represents the variance of the score process n1/2U(Ω0). In addition, Andersen
et al. (2012) showed that for a differentiable functional F (Ω), by functional delta
method, n1/2{F (Ω̂)−F (Ω)} converges weakly to a zero-mean Gaussian process with
variance-covariance function Ḟ (Ω)T I−1∞ Ḟ (Ω), where Ḟ (Ω) =
∂F
∂Ω
. Applying it to the
linear functional defined in Theorem II.2, and replacing I∞ by its consistent estimator
In, we can have the stated results.
A.5.4 Proof of Theorem II.3
As we defined in the proof of Theorem II.2,












is the asymptotic covariance matrix operator of the score for the full model. Apply













where Q = Iββ − IβHI−1HHIHβ.

























. We prove it in two steps: First,





= Q−1. Then, we prove that Iprββ
−1 p−→ Q−1.




= Q−1 is as follows:

















which is a martingale under the true model.

































































0)], as shown in equation (A.5). Therefore, we have
cov[
√










n(Ω̂− Ω0)] = I−1∞ cov[
√




n(β̂ − β0)] = Q−1.

































Since dĤβ solves the score equation
∂l
∂dH(s)


























































































=JβH ÎHHJHβ − 0 + JβH ÎHβ − 0 + ÎβHJHβ + Îββ
=JβH ÎHHJHβ + JβH ÎHβ + ÎβHJHβ + Îββ.




























= −ÎHβ − ÎHHJHβ
=⇒ JHβ = −Î−1HH Î
−1
Hβ
Replace the Jacobians in Iprββ with the expression above, we have
Iprββ = Îββ − ÎβH Î
−1
HH ÎHβ
p−→ Iββ − IβHI−1HHIHβ = Q.
Thus,
Iprββ





A Semiparametric Joint Model for Estimating the
Screening Effect on Cancer Mortality
B.1 Prediction of survival function for the terminal event
This section presents the derivation of conditional survival functions of termi-
nal event given incidence information at time t∗. Specifically, we are interested in
Pr(TD > t|X1 = t∗,∆1). For t ≥ t∗,
1. Consider a subject that has been diagnosed at t∗, i.e. ∆1 = 1, TI = t
∗
Pr(TD > t|TI = t∗) =
Pr(TI = t










∗|tD) dtD + fTD(∞)fTI |TD(t∗|∞)∫ tlf2
t∗
fTD(tD)fTI |TD(t






























2. Consider a subject that has not been diagnosed at t∗, i.e. ∆1 = 0, TI > t
∗
Pr(TD > t|TI > t∗) =
Pr(TI > t











fTD(tD)fTI |TD(tI |tD) dtIdtD +
∫∞
t∗




fTD(tD)fTI |TD(tI |tD) dtIdtD +
∫∞
t∗








































B.2 Derivation of hazard terms
For ease of notation, we suppress the subscript i for each individual subject.
1. The hazard of having incidence at time t:
dΛ1(t) = Pr
(









































2. The hazard of dying from cancer at time t, given incidence at time t1:
dΛ2(t|t1) = Pr[dN2(t|t1) = 1|Y2(t|t1) = 1]
=
Pr(TI = t1, TD = t)

























This section presents the derivation of EM algorithm to estimate the nonparamet-
ric components {dH} and {h} for our model. When the terminal event is censored,
we introduce an artificial variable U to transform the likelihood, and treating this
artificial variable and the censored terminal event as missing data, an EM algorithm
is derived to obtain {dH} and {h}.








Here, L0 is the conditional likelihood of the incidence event, given the terminal event
observed at TD = tD and U ; and P0 is the joint likelihood of TD and U .
In the (k+1)th iteration,
E-step: Unconditional score function








M-step: Set U(s) = 0, then we can obtain dH(k+1)(s) to update the expression of
dH(s).
Similar steps are taken to iteratively update the estimates of h(s).
The rest of this section is organized as follows. First, we write out the conditional
score function for {dH} and {h}, for the three different cases respectively (both events
observed, incidence observed yet death censored, and neither events observed). Next
we derive the E step for {dH} and {h}. Finally we derive the M step to maximize
the likelihood with respect to {dH} and {h}, which has a closed-form expression
analogous to the weighted Breslow-type estimators of Chen (2009).
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B.3.1 EM algorithm for {dH}
B.3.1.1 Conditional score function





1. Subject has incidence at X1, and dies at X2 (i.e. ∆1 = 1, ∆2 = 1):













− η1(X2 ≥ s).
2. Subject has incidence at X1, and is censored at X2 (i.e. ∆1 = 1, ∆2 = 0):
(a) If X2 ≥ tlf2:










U0,dH(s) = −η1(tlf2 ≥ s).
(b) If X2 < tlf2:
Since terminal event TD is not observed, an artificial variable U is intro-
duced to simplify computation, and the complete data is (TI = X1, TD =
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tD, U = u),
Lcom =

h(X1)µ(X1)ηdH(tD) exp{−ηH(tD)− u[1 +
∑
k:0<tk≤tD
h(tk)µ(tk)]}, tD ≤ tlf2









− η1(TD ≥ s), TD ≤ tlf2
−η1(tlf2 ≥ s), TD =∞.
3. Subject is censored at X2 before any event is observed (i.e. ∆1 = 0, ∆2 = 0):
(a) If X2 ≥ tlf1:









U0,dH(s) = −η1(tlf2 ≥ s).
(b) If X2 < tlf1 and X2 ≥ tlf2:
In this case, incidence event TI occurs after time X2, and death TD occurs











U0,dH(s) = −η1(tlf2 ≥ s).
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(c) If X2 < tlf1 and X2 < tlf2:
Incidence and death events are both censored, and likelihood for the com-





h(tk)µ(tk)]ηdH(tD) exp{−ηH(tD)− u[1 +
∑
k:0<tk≤tD













− η1(TD ≥ s), TD ≤ tlf2
−η1(tlf2 ≥ s), TD =∞.
B.3.1.2 E step
The unconditional score function for {dH} is








In the rest of EM algorithm section, we keep iteration index for (k + 1)th iteration
when needed, and drop index for kth for brevity. Note that the denominator E[L
(k)
0 ]
is just observed data likelihood, as in Section 3.2.4.
1. Subject has incidence at X1, and dies at X2 (i.e. ∆1 = 1, ∆2 = 1)
Since there is no missingness, the unconditional score function is




2. Subject has incidence at X1, and is censored at X2 (i.e. ∆=1, ∆2 = 0)
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(a) If X2 ≥ tlf2:
UdH(s) = U0,dH(s) = −η1(tlf2 ≥ s).
(b) If X2 < tlf2:
First, we write out L0 and P0. P0 is the distribution of missing data
(TD, U):
P0 = fTD(tD)fU(u) =

ηdH(tD)e
−ηH(tD)−u, tD ≤ tlf2
e−ηH(tlf2)−u, tD =∞.
L0 is the conditional incidence given TD and U , and in this case,




Next, we calculate the numerator E[U0,dH(s)L0], and finally obtain the
unconditional score function UdH(s). Note, the denominator E[L
(k)


















= h(X1)µ(X1)[U(X2, tlf2) + V ].
We consider the calculation in three cases, s ≤ X2, X2 < s ≤ tlf2, and
s > tlf2, respectively.
• s ≤ X2, i.e. Y2(s) = 1
First, based on conditional score function derived in Appendix B.3.1.1,
U0,dH(s) = −η, which does not depend on any missing data.
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− η1(TD ≥ s), TD ≤ tlf2
−η, TD =∞.
Then the numerator E[U0,dH(s)L0]
=
E[1(TD = s)1(TD ≤ tlf2)L0]
dH(k+1)(s)
− ηE[1(s ≤ TD ≤ tlf2)L0]− ηE[1(TD =∞)L0]
We can derive the term E[1(TD = s)1(TD ≤ tlf2)L0] as















The term E[1(s ≤ TD ≤ tlf2)L0] can be derived as














































− h(X1)µ(X1)[ηU(s−, tlf2) + ηV − U.s].






U.s− [ηU(s−, tlf2) + ηV − U.s]
U(X2, tlf2) + V
.
• s > tlf2, i.e. Ylf2(s) = 0
Since U0,dH(s) = 0, the unconditional score function UdH(s) is also zero.
Combining these results, the contribution of a subject, with intermediate event
observed at X1 yet terminal event censored at X2, to the unconditional score






1(X2 < tlf2)[1− Y2(s)]
U.s
U(X2, tlf2) + V
−
{
1(X2 ≥ tlf2)η+1(X2 < tlf2)
{
Y2(s)η+[1−Y2(s)]
η[U(s−, tlf2) + V ]− U.s




3. Subject is censored at X2 before any event is observed (i.e. ∆1 = 0, ∆2 = 0)
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(a) If X2 ≥ tlf1:
UdH(s) = U0,dH(s) = −η1(tlf2 ≥ s).
(b) If X2 < tlf1 and X2 ≥ tlf2:
UdH(s) = U0,dH(s) = −η1(tlf2 ≥ s).
(c) If X2 < tlf1 and X2 < tlf2:
First we need P0 and L0. P0 keeps the same distribution as before, and







Then we calculate UdH(s) in three cases, s ≤ X2, X2 < s ≤ tlf2, and
s > tlf2. Note, the denominator E[L
(k)






















= W (X2, tlf2) + Z.
• s ≤ X2, i.e. Y2(s) = 1
Since U0,dH(s) = −η, UdH(s) = −η.
• X2 < s ≤ tlf2, i.e. Y2(s) = 0, Ylf2(s) = 1





− η1(TD ≥ s), TD ≤ tlf2
−η, TD =∞.
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Then the numerator E[U0,dH(s)L0] is
E[1(TD = s)1(TD ≤ tlf2)L0]
dH(k+1)(s)
− ηE[1(s ≤ TD ≤ tlf2)L0]− ηE[1(TD =∞)L0].
We can derive the term E[1(TD = s)1(TD ≤ tlf2)L0] as




















The term E[1(s ≤ TD ≤ tlf2)L0] can be derived as























dH(tD) = W (s
−, tlf2).





























W.s− [ηW (s−, tlf2) + ηZ −W.s].






W.s− [ηW (s−, tlf2) + ηZ −W.s]
W (X2, tlf2) + Z
.
• s > tlf2, i.e. Ylf2(s) = 0
Since U0,dH(s) = 0, UdH(s) is also zero.
Combining these results, the contribution of a subject, with both intermediate







1(X2 < tlf1)1(X2 < tlf2)[1− Y2(s)]
W.s
W (X2, tlf2) + Z
−
{
1(X2 < tlf1)1(X2 < tlf2)
{
Y2(s)η + [1− Y2(s)]
η[W (s−, tlf2) + Z]−W.s



























− η + Y2(s)η + [1− Y2(s)]
η[U(s−, tlf2) + V ]− U.s
U(X2, tlf2) + V
}
+(1−∆1)1(X1 < tlf1)1(X2 < tlf2)
{
− η + Y2(s)η
+ [1− Y2(s)]
η[W (s−, tlf2) + Z]−W.s
W (X2, tlf2) + Z
}
,




U(X2, tlf2) + V
+ 1(X1 < tlf1)(1−∆1)
W.s




Suppose we have n independent subjects with observed data (X1i,∆1i, X2i,∆2i),





































The above equation solves for dH(s) iteratively until convergence, and the estimator
at convergence, d̂H(s), is a consistent estimator of dH(s) (Tsodikov (2003)).
121
B.3.2 EM algorithm for {h}
B.3.2.1 Conditional score function















2. Subject has incidence at X1, and is censored at X2 (i.e. ∆1 = 1, ∆2 = 0):















− µ(s)U1(TD ≥ s), TD ≤ tlf2
1(X1 = s)
h(s)
− µ(s)U, TD =∞.
3. Subject is censored at X2 before any event is observed (i.e. ∆1 = 0, ∆2 = 0):























(c) If X2 < tlf1 and X2 < tlf2:
U0,h(s) =

1(X2 < s ≤ TD)∑
k:X2<tk≤TD
h(tk)µ(tk)




1(X2 < s)− µ(s)U, TD =∞.
B.3.2.2 E step
The unconditional score function for {h} is








1. Subject has incidence at X1, and dies at X2 (i.e. ∆1 = 1, ∆2 = 1)
Since there is no missingness, the unconditional score function is









2. Subject has incidence at X1, and is censored at X2 (i.e. ∆I = 1, ∆D = 0)
(a) If X2 ≥ tlf2:









(b) If X2 < tlf2:
First we have the conditional score function U0,h(s)as in Appendix B.3.1.1.
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Next, we calculate the numerator E[U0,dH(s)L0], and finally obtain the
unconditional score function UdH(s). We consider the calculation in three
cases, s ≤ X2, X2 < s ≤ tlf2, and s > tlf2, respectively.











































= h(X1)µ(X1)[P (X2, tlf2) +Q].




E[L0]− µ(s)h(X1)µ(X1)[P (X2, tlf2) +Q].







− µ(s)P (X2, tlf2) +Q
U(X2, tlf2) + V
.
124
• X2 < s ≤ tlf2, i.e. Y2(s) = 0, Ylf2(s) = 1
First, the conditional score function for h(s)
U0,h(s) =

−µ(s)U1(TD ≥ s), TD ≤ tlf2
−µ(s)U, TD =∞.
Then the numerator E[U0,h(s)L0] can be written as
E[U0,h(s)L0] = −µ(s)E[1(s ≤ TD ≤ tlf2)UL0]− µ(s)E[1(TD =∞)UL0].

















ηe−ηH(tD)dH(tD) = h(X1)µ(X1)P (s
−, tlf2).
The term E[1(TD =∞)UL0] is







So the numerator is calculated as
E[U0,h(s)L0] = −µ(s)h(X1)µ(X1)[P (s−, tlf2) +Q].






U(X2, tlf2) + V
.
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• s > tlf2, i.e. Ylf2(s) = 0
The conditional score function for h(s) is
U0,h(s) =

0, TD ≤ tlf2
−µ(s)U, TD =∞.
Then the numerator E[U0,h(s)L0] can be calculated as
E[U0,h(s)L0] = −µ(s)E[1(TD =∞)UL0] = −µ(s)h(X1)µ(X1)Q.





U(X2, tlf2) + V
.
Combining these results, the contribution of a subject, with intermediate event
observed at X1 yet terminal event censored at X2, to the unconditional score










Q+ Y2(s)P (X2, tlf2) + [1− Y2(s)]Ylf2(s)P (s−, tlf2)
U(X2, tlf2) + V
}
. (B.5)
3. Subject is censored at X2 before any event is observed (i.e. ∆1 = 0, ∆2 = 0)
(a) If X2 ≥ tlf1:










(b) If X2 < tlf1 and X2 ≥ tlf2:










(c) If X2 < tlf1 and X2 < tlf2:
We consider UdH(s) in three cases, s ≤ X2, X2 < s ≤ tlf2, and s > tlf2,
respectively. Note, the denominator E[L
(k)
0 ] is the observed data likelihood
E[L0] = Lobs,00 = W (X2, tlf2) + Z.
• s ≤ X2, i.e. Y2(s) = 1
First, conditional score function is U0,h(s) = −µ(s)U .












































= −µ(s)(R + V − T ).




= −µ(s) R + V − T
W (X2, tlf2) + Z
.
• X2 < s ≤ tlf2, i.e. Y2(s) = 0, Ylf2(s) = 1
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µ(s)− µ(s)U, TD =∞.
Next the numerator E[U0,h(s)L0] can be calculated as
E[U0,h(s)L0]
= µ(s)E[
1(s ≤ TD ≤ tlf2)∑
k:X2<tk≤TD
h(tk)µ(tk)





E[1(TD =∞)L0]− µ(s)E[1(TD =∞)UL0].
The term E[
1(s ≤ TD ≤ tlf2)∑
k:X2<tk≤TD
h(tk)µ(tk)
























The term E[1(s ≤ TD ≤ tlf2)UL0] is derived as











































































e−ηH(tlf2) = V − T.
The numerator E[U0,h(s)L0] is calculated as
E[U0,h(s)L0] = µ(s)[U(s
−, tlf2)− [U(s−, tlf2)− S2] + V − (V − T )]
= µ(s)(S2 + T ).






W (X2, tlf2) + Z
.
• s > tlf2, i.e. Ylf2(s) = 0
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First, conditional score function U0,h(s) is
U0,h(s) =





µ(s)− µ(s)U, TD =∞.






E[1(TD =∞)L0]− µ(s)E[1(TD =∞)UL0]
= µ(s)(V + V − T ) = µ(s)[V − (V − T )] = µ(s)T.






W (X2, tlf2) + Z
.
Combining these results, the contribution of a subject, with both intermediate
















+1(X2 < tlf1)1(X2 < tlf2)
−T + Y2(s)(R + V )− [1− Y2(s)]Ylf2(s)S2






























+ 1(X2 < tlf1)1(X2 < tlf2)
−T + Y2(s)(R + V )− [1− Y2(s)]Ylf2(s)S2








Q+ Y2(s)P (X2, tlf2) + [1− Y2(s)]Ylf2(s)P (s−, tlf2)




Suppose we have n independent subjects with observed data (X1i,∆1i, X2i,∆2i),























The above equation solves for h(s) iteratively until convergence, and the estimator
at convergence, ĥ(s), is a consistent estimator of h(s) (Tsodikov (2003)).
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APPENDIX C
A Mechanistic Joint Model to Investigate the
Screening Effect on Cancer Mortality
C.1 Complete-data Likelihood
The complete-data likelihood Lcom for a single subject is:
Lcom = L0f1(t1),
where L0 is the conditional likelihood of observed data, given T1, which can be seen
from (4.4), (4.5) and (4.6); and f1(t1) is the distribution of T1,
f1(t1) = µ1dHI(t1)e
−µ1HI(t1). Then we can obtain Lcom in the following three cases:
1. Subject has incidence at XI , and dies at XD (i.e. ∆I = 1, ∆D = 1):
Lcom =
ηµ1dHI(XI)dHD(XD)e
−(µ1+µ2)HI(XI)−η[HD(XD)−HD(XI)], T1 = XI
ηµ1µ2dHI(t1)dHI(XI)dHD(XD)e
−µ1HI(t1)−µ2HI(XI)−η[HD(XD)−HD(t1)], T1 ∈ (XI , XD]
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−(µ1+µ2)HI(XI)−η[HD(XD)−HD(XI)], T1 = XI
µ1µ2dHI(t1)dHI(XI)e
−µ1HI(t1)−µ2HI(XI)−η[HD(XD)−HD(t1)], T1 ∈ (XI , XD]
µ1µ2dHI(XI)dHI(t1)e
−µ1HI(t1)−µ2HI(XI), T1 > XD.
3. Subject is censored at XI before any event is observed (i.e. ∆I = 0, ∆D = 0):
Lcom = µ1dHI(t1)e
−µ1HI(t1)−µ2HI(XI), T1 > XI .
C.2 Prediction of Survival Function for Causal Incidence
Prediction of time to causal incidence is of interest in analysis. In this section, we
derive the survival functions for causal incidence, given observed data and estimates
of η, µ1, µ2, {dHI} and {dHD}:
ST1(t1|Observed Data)
= P (T1 > t1|Observed Data)
=








Note the denominator is the observed data likelihood (4.10), and Lcom in the numer-
ator is the complete data likelihood in Appendix C.1. The survival function can be
derived in the following three conditions:
1. Subject has incidence at XI , and dies at XD (i.e. ∆I = 1, ∆D = 1):







where L11 is the observed likelihood for ∆I = 1, ∆D = 1 as (4.7).
• If t1 < XI ,
∞∫
t1

























After some algebra, we obtain the conditional survival function for causal inci-
dence T1, given observed incidence at XI and observed death at XD as:
ST1(t1|XI , XD,∆I = 1,∆D = 1)
=










, t1 ∈ [XI , XD]
0, t1 > XD.
2. Subject has incidence at XI , and is censored at XD (i.e. ∆I = 1, ∆D = 0):
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where L10 is the observed likelihood for ∆I = 1, ∆D = 0 as (4.8).
• If t1 < XI ,
∞∫
t1













































Therefore, we can obtain the conditional survival function for causal incidence
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T1, given observed incidence at XI and terminal event censored at XD as:
ST1(t1|XI , XD,∆I = 1,∆D = 0)
=






















, t1 > XD.
3. Subject is censored at XI before any event is observed (i.e. ∆I = 0, ∆D = 0):






where L00 is the observed likelihood for ∆I = 0, ∆D = 0 as (4.9).
















Then, the conditional survival function for causal incidence T1, given neither
event observed before XI is:
ST1(t1|XI , XD,∆I = 0,∆D = 0) =

1, t1 < XI
e−µ1[HI(t1)−HI(XI)], t1 ≥ XI .
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C.3 Derivation of Hazard Terms
For ease of notation, we suppress the subscript i for each individual subject.
1. The hazard of having incidence at time t:
dΛI(t) = ΘI(t)dHI(t) = Pr
(
dNI(t) = 1|YI(t) = 1
)
= (µ1 + µ2)dHI(t)
⇒ ΘI(t) = µ1 + µ2.
2. The hazard of dying from cancer at time t, given incidence at time tI :
dΛD(t; tI) = ΘD(t; tI)dHD(t) = Pr
(
dND(t) = 1|YD(t) = 1, dNI(tI) = 1
)
=
Pr(TD = t, TI = tI)

















C.4 Derivation of Score Function












































where dΛIi(t) = ΘIi(t)dHI(t) and dΛDi(t) = ΘDi(t)dHD(t).
Taking derivatives of l, with respect to β, dHI(s), and dHD(s), respectively, we
can obtain the corresponding score functions. Since l = lI + lD, score function U =
UI + UD.































































































































































Finally, since U(·) = UI,(·) +UD,(·), and in our model, Θ̇Ii,dHI(s)(t) = Θ̇Ii,dHD(s)(t) =












































This section presents the derivation of EM algorithm to estimate the baseline
hazards of both intermediate and terminal events for our model, using the methods
of Tsodikov (2003):
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In the (k+1)th iteration,
E-step: Unconditional score function








M-step: Set U(s) = 0, then we can obtain dH(k+1)(s) to update the expression of
dH(s).
The rest of this section is organized as follows. First, we write out the conditional
score function for baseline hazard of incidence {dHI}, for the three different cases
respectively (both events observed, incidence observed yet death censored, and neither
events observed). Next we derive the E step for {dHI}. Finally we derive the M step
to maximize the likelihood with respect to {dHI}, which has a closed-form expression
analogous to the weighted Breslow-type estimators of Chen (2009). Similar steps are
taken to derive the EM algorithm for baseline hazard of death {dHD}. The following
notations are introduced




W (s) = eηHD(s)−µ1HI(s).
C.5.1 Conditional score functions
















− µ11(T1 ≥ s)− µ21(XI ≥ s), T1 ∈ (XI , XD].










− µ11(T1 ≥ s)− µ21(XI ≥ s), T1 > XI .





− µ11(T1 ≥ s)− µ21(XI ≥ s), T1 > XI .










− η[1(XD ≥ s)− 1(XI ≥ s)], T1 = XI
1(XD=s)
dHD(s)
− η[1(XD ≥ s)− 1(T1 ≥ s)], T1 ∈ (XI , XD].
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• Subject has incidence at XI , and is censored at XD (i.e. ∆I = 1, ∆D = 0):
U0,dHD(s) =

−η[1(XD ≥ s)− 1(XI ≥ s)], T1 = XI
−η[1(XD ≥ s)− 1(T1 ≥ s)], T1 ∈ (XI , XD]
0, T1 > XD.




The unconditional score functions are


















In the rest of EM algorithm section, we keep iteration index for (k + 1)th iteration
when needed, and drop index for kth for brevity. Note that the denominator E[L
(k)
0 ]
is just observed data likelihood, as (4.10).
1. Subject has incidence at XI , and dies at XD (i.e. ∆I = 1, ∆D = 1)
First, the denominator E[L
(k)
0 ] is the observed data likelihood (4.7), and can be
rewritten as
E[L0] = Lobs,11 = ηµ1dHI(XI)dHD(XD)e
−µ2HI(XI)−ηHD(XD)[W (XI)+µ2V (XI , XD)].
Next, we calculate the numerators E[U0,dHI (s)L0] and E[U0,dHD(s)L0], and final-
ly obtain the unconditional score functions UdHI (s) and UdHD(s). Since U0,dHI (s)
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and U0,dHD(s) depend on s, we consider the calculation in three cases, s ≤ XI ,
XI < s ≤ XD, and s > XD, respectively.
(a) s ≤ XI , i.e. YI(s) = 1, YD(s) = 1
Based on conditional score functions derived in Appendix C.5.1,






− (µ1 + µ2),
since U0,dHI (s) does not depend on the unobserved T1,





− (µ1 + µ2)
]
E[L0].









− (µ1 + µ2).
• Similarly, we can obtain that U0,dHD(s) = 0, then E[U0,dHD(s)L0] = 0.
Thus, the unconditional score function for dHD(s),
UdHD(s) = 0.
(b) XI < s ≤ XD, i.e. YI(s) = 0, YD(s) = 1
• To calculate UdHI (s), first
U0,dHI (s) =














−µ1E[1(T1 ≥ s)L0], T1 ∈ (XI , XD].
Expression of conditional likelihood L0 is given as (4.4) in Section
























W (s)− µ1V (s−, XD)
]
.








W (s)− µ1V (s−, XD)
W (XI) + µ2V (XI , XD)
.
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− η W (XI) + µ2V (XI , s
−)
W (XI) + µ2V (XI , XD)
.
(c) s > XD, i.e. YI(s) = 0, YD(s) = 0
U0,dHI (s) = U0,dHD(s) = 0.
Thus, the unconditional score functions
UdHI (s) = UdHD(s) = 0.
Combining these results, the contribution of a subject, with both intermediate
and terminal events observed atXI andXD, to the unconditional score functions
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W (XI) + µ2V (XI , XD)
−
{
YI(s)(µ1 + µ2) + YD(s)[1− YI(s)]µ2
µ1V (s
−, XD)−W (s)









W (XI) + µ2V (XI , s
−)
W (XI) + µ2V (XI , XD)
. (C.1)
2. Subject has incidence at XI , and is censored at XD (i.e. ∆I = 1, ∆D = 0)
We now proceed through the same steps as for the case ∆I = ∆D = 1. In this
case, the denominator E[L
(k)




−µ2HI(XI)−ηHD(XD)[µ1W (XI) + µ1µ2V (XI , XD) + µ2W (XD)].
Then, we calculate UdHI (s) and UdHD(s) in three cases, s ≤ XI , XI < s ≤ XD,
and s > XD, respectively.
(a) s ≤ XI , i.e. YI(s) = 1, YD(s) = 1






− (µ1 + µ2),
which does not depend on the unobserved T1.
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• To calculate UdHD(s), since U0,dHD(s) = 0, then E[U0,dHD(s)L0] = 0.
Thus, the unconditional score function for dHD(s),
UdHD(s) = 0.
(b) XI < s ≤ XD, i.e. YI(s) = 0, YD(s) = 1
• To calculate UdHI (s), first
U0,dHI (s) =






− µ11(T1 ≥ s), T1 ∈ (XI , XD],
−µ1, T1 > XD.
Then the numerator
E[U0,dHI (s)L0] =




− µ1E[1(s ≤ T1 ≤ XD)L0]− µ1E[1(T1 > XD)L0].
Expression of conditional likelihood L0 is given as (4.5) in Section
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4.2.3. Then, the first term is derived as

















The term E[1(s ≤ T1 ≤ XD)L0] can be derived as








The term E[1(T1 > XD)L0] can be derived as




















− µ21µ2dHI(XI)e−µ2HI(XI)−ηHD(XD)V (s−, XD)
− µ1µ2dHI(XI)W (XD)e−µ2HI(XI)−ηHD(XD).
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W (s)− µ1V (s−, XD)−W (XD)
µ1W (XI) + µ1µ2V (XI , XD) + µ2W (XD)
.
• To calculate UdHD(s), first
U0,dHD(s) =

−η, T1 = XI ,
−η + η1(T1 ≥ s), T1 ∈ (XI , XD],
0, T1 > XI .
Then the numerator
E[U0,dHD(s)L0] =− ηE[1(T1 = XI)L0]− ηE[1(XI ≤ T1 ≤ XD)L0]
+ ηE[1(T1 ≥ s)1(XI < T1 ≤ XD)L0]
=− ηµ1dHI(XI)e−µ2HI(XI)−ηHD(XD)W (XI)









Thus, the unconditional score function for dHD(s)
UdHD(s) = −ηµ1
W (XI) + µ2V (XI , s
−)
µ1W (XI) + µ1µ2V (XI , XD) + µ2W (XD)
.
(c) s > XD, i.e. YI(s) = 0, YD(s) = 0
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• To calculate UdHI (s), first
U0,dHI (s) =






− µ11(T1 ≥ s), T1 > XD.
Then, the numerator E[U0,dHI (s)L0] is




− µ1E[1(T1 ≥ s)1(s > XD)L0].
The term E[1(T1 = s)1(s > XD)L0] can be derived as
E[1(T1 = s)1(s > XD)L0] = µ1µ2dHI(s)dHI(XI)e
−µ1HI(s)−µ2HI(XI),
and the term E[1(T1 ≥ s)1(s > XD)L0] can be derived as






























µ1W (XI) + µ1µ2V (XI , XD) + µ2W (XD)
.
• To calculate UdHD(s), since U0,dHD(s) = 0, UdHD(s) is also zero.
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Combining these results, the contribution of a subject, with intermediate event
observed at XI yet terminal event censored at XD, to the unconditional score

















YD(s)[1− YI(s)]W (s) + [1− YD(s)]eηHD(XD)−µ1HI(s)





−, XD) +W (XD)−W (s)
µ1W (XI) + µ1µ2V (XI , XD) + µ2W (XD)
}
,
UdHD(s) = −YD(s)[1− YI(s)]ηµ1
W (XI) + µ2V (XI , s
−)
µ1W (XI) + µ1µ2V (XI , XD) + µ2W (XD)
.
(C.2)
3. Subject is censored at XI before any event is observed (i.e. ∆I = 0, ∆D = 0)
In this case, the denominator E[L
(k)
0 ] is the observed data likelihood (4.9), so
E[L0] = Lobs,00 = e
−(µ1+µ2)HI(XI).
Then, we calculate the numerators E[U0,dHI (s)L0] and E[U0,dHD(s)L0], and fi-
nally obtain the unconditional score functions UdHI (s) and UdHD(s).





For the calculation of UdHI (s), we consider two cases: s ≤ XI and s > XI .
(a) s ≤ XI , i.e. YI(s) = YD(s) = 1
We first consider the conditional score function for dHI(s)
U0,dHI (s) = −(µ1 + µ2),
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which does not depend on the unobserved T1.
Then, the unconditional score function for dHI(s)
UdHI (s) = U0,dHI (s) = −(µ1 + µ2).
(b) s > XI , i.e. YI(s) = YD(s) = 0













− µ1E[1(T1 ≥ s)L0].
The term E[1(T1 = s)L0] can be written as
E[1(T1 = s)L0] = µ1dHI(s)e
−µ1HI(s)−µ2HI(XI).
The term E[1(T1 ≥ s)L0] can be derived as













































Combining these results, the contribution of a subject, censored at XI before
any event is observed, to the unconditional score functions can be written as











UdHD(s) = 0. (C.3)

























ΨI(s) = YI(s)(µ1 + µ2)
+∆IYD(s)[1− YI(s)]µ1µ2
µ1V (s
−, XD)−W (s) + (1−∆D)W (XD)
µ1W (XI) + µ1µ2V (XI , XD) + (1−∆D)µ2W (XD)
,
θI(s) = (1−∆I)[1− YD(s)]µ1eµ1HI(XI)−µ1HI(s)
+ ∆Iµ1µ2
YD(s)[1− YI(s)]W (s) + [1− YD(s)](1−∆D)eηHD(XD)−µ1HI(s)
µ1W (XI) + µ1µ2V (XI , XD) + (1−∆D)µ2W (XD)
,
ΨD(s) = ∆IYD(s)[1− YI(s)]ηµ1
W (XI) + µ2V (XI , s
−)




Suppose we have n independent subjects with observed data (XIi,∆Ii, XDi,∆Di),
i = 1, 2, ..., n. The estimator of dH
(k+1)
I (s) can be derived by solving
n∑
i=1
Ui,dHI (s) = 0.









































The above equation solves for dHI(s) iteratively until convergence, and the estimator
at convergence d̂HI(s) is a consistent estimator of dHI(s) (Tsodikov (2003)).


























which can be solved iteratively.
C.6 Asymptotic Properties
This section presents the technical details of the asymptotic properties of the
NPMLE Ω̂ = (β̂, {dĤI}, {dĤD}), adapted from Hu and Tsodikov (2014), Supple-
mentary Materials C and Rice and Tsodikov (2017), Appendix F. To establish the
asymptotic properties, we assume the following conditions are satisfied (Fleming and
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Harrington (2011), p289-p290):
1. The true values of baseline hazards H0I and H
0
D are strictly increasing and
differentiable. The true parameter set Ω0 is in the interior of the compact
convex set H.
2. With probability 1, P [YD(t)|z] > 0, P [∆D = 0, XD = τ |z] > 0. The at risk set
will not shrink to zero.
3. The Hessian matrix In evaluated at the true value Ω0 = (β0, dH0I , dH0D) is
positive definite, and converges in probability to a deterministic and invertible
operator I0.
4. The model is identifiable such that




D) uniformly over Ω ⇒ Ω = Ω0.
C.6.1 Proof of Theorem IV.1
To prove consistency: |Ω̂−Ω0| p−→ 0, based on Theorom 2.12 of Kosorok (2008),
in addition to the regularity conditions provided above, another three conditions need
to be verified:
(a) ln(Ω̂n) = supΩ∈H ln(Ω)− op(1)
(b) Identifiability condition 2: For any sequence Ωn ∈ H,
lim infn→∞l(Ωn) ≥ l(Ω0) ⇒ ‖Ωn − Ω0‖
p−→ 0.
(c) Uniform convergence condition: supΩ∈H |ln(Ω)− l(Ω)|
p−→ 0.
Note, Ω̂n here is the maximum likelihood estimator of Ω, which is Ω̂ in our previous
notation.
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We verify the three conditions as follows:
1. To verify condition (a), Ω̂n is the maximum estimator of Ω, thus condition (a)
is satisfied.
2. To verify condition (b), by Lemma 14.3 of Kosorok (2008), we just need to prove
that l(Ω) is upper semicontinuous with a unique maximum at Ω0.
The model is characterized by defining the hazard functions as
dΛI(t) = ΘI(t; Ω)dHI(t) and dΛD(t) = ΘD(t; Ω)dHD(t),
which are both functions of Ω. Let FI(t) and FD(t) be the cumulative den-
sity functions for incidence and death, subject to censoring; and let SI(t)





I (t) and S
0
D(t) denote the corresponding true functions. Note that








I (t)−S0I (t)dΛI(t)+log dΛD(t)dF 0D(t)−S0D(t)dΛD(t)
}
,
where the expectation is taken over covariate z.






dF 0I (t)[log dΛI(t)− log dΛ0I(t)]− S0I (t)[dΛI(t)− dΛ0I(t)]





dF 0(t)[log dΛ(t)− log dΛ0(t)]− S0(t)[dΛ(t)− dΛ0(t)]

























































where ρ(x) = log x − x + 1 is a non-positive convex function, with a unique






= 1, i.e., dΛI(t) = dΛ
0
I(t) and dΛD(t) = dΛ
0
D(t).
Given regularity condition 4, under the identifiable model, D has a unique
maximum at Ω0. Since maximizing D is equivalent to maximizing l(Ω), we can
conclude that l(Ω) has a unique maximum at Ω0. We also know l(Ω) is upper
semicontinuous, thus condition (b) holds.
3. To verify condition (c), given regularity condition 1, Ω is in the class of functions
of bounded variation with integrable envelope, so HI(t) and HD(t) are bounded.
Therefore, H is a Glivenko-Cantelli class. Then, since the functionals ΛI , ΛD
and l(Ω) are continuous, and the envelope function is integrable, then by the
preservation of Glivenko-Cantelli theorem (Van Der Vaart and Wellner (2000)),
the integrand in l(Ω) is also Glivenko-Cantelli. Therefore, we apply the uniform
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C.6.2 Martingale Representation of Score Functions
In this part, we justify that the score functions for HI(t), HD(t) and β are all
martingales under the true model.
Based on equations (4.12) and (4.13), we integrate the expression over dHI(s)
and dHD(s), respectively, normalize them by 1/n, and obtain the normalized score































































HD(x ∧ t) + 1(t < x)
}
dMDi(t),
We first consider the score function UHI(x). Similar as the proof in (Hu and Tsodikov
(2014), Supplementary Materials B),
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Let εI(t, x) =
Θ̇D,dHI (t)
ΘD(t)
HI(x ∧ t), εD(t, x) =
Θ̇D,dHD (t)
ΘD(t)






















Consider the increment of UHI(x) over x,
dUHI (x) = UHI(x+dx) − UHI(x) = dMI(x) +
τ∫
0







Take the expectation conditional on filtration F(x−),







The first term E[dMI(x)|F(x−)] = 0, based on the martingale property of MI(x).
εI(t, x) depends on t when t < x,
∂εI(t,x)
∂x
= 0 when t < x. E[dMD(t)|F(x−)] = 0, if






























Thus, E[dUHI (x)|F(x−)] = 0, and UHI (x) is a martingale.
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Similarly, we can also conclude that UHD(x) is a martingale under the true model.




































is a martingale. Thus, the score function
with respect to β is also a martingale under the true model.
C.6.3 Proof of Theorem IV.2
We prove Theorem IV.2 in two steps. Suppose U(Ω) = (Uβ, UHI(t), UHD(t))
T is
the set of score functions for parameter set Ω. First, we prove the weak convergence
of the score functions at the true parameter n1/2U(Ω0) by Martingale Central Limit
Theorem (MCLT). Then, we seek for the relationship between n1/2(Ω̂ − Ω0) and
n1/2U(Ω0), to obtain the weak convergence of the NPMLE Ω̂.
Based on the martingale representation of U(Ω0) in Appendix C.6.2, and the fact
that NIi and NDi, i = 1, 2, ..., n, are orthogonal, it follows that n
1/2U(Ω0) converges
weakly to a zero-mean Gaussian process with its variance-covariance function char-
acterized by σ2β(Ω
0), σ2HI (x, y; Ω





0) as derived below.
160






































P (TI ≥ t)dHI(t) +
Θ̇2D,β(t)
ΘD(t)
P (TD ≥ t)dHD(t)
}
.









P (TI ≥ t)dHI(t) +
Θ̇2D,β(t)
ΘD(t)




n1/2UHI converges weakly to a zero-mean Gaussian process with covariance function






1(t ≤ x)1(t ≤ y)P (TI ≥ t)ΘI(t)dHI(t)+εI(t, x)εI(t, y)P (TD ≥ t)ΘD(t)dHD(t)
}
,
for x, y ∈ [0, τ ];











































εI(t, x)εD(t, y)P (TD ≥ t)ΘD(t)dHD(t).













, where dH(t) = (dHI(t), dHD(t)). Define a linear infor-
mation operator I∞ as



















I∞(t, s)Ωs = −















With Taylor expansion, expand U(Ω̂) at the true parameter Ω0, we have
U(Ω̂) = 0 = U(Ω0)− I∞(t, s)(Ω̂− Ω0) + op(1)
⇒ I∞(t, s)n1/2(Ω̂− Ω0) = n1/2U(Ω0) + op(1). (C.7)
Assume that the Fredholm operator expressed by the kernel I∞ of the Fredholm
integral equations (C.7) of the first kind is square integrable, and the equation I∞Ω =
0 has only the trivial solution Ω = 0. Then based on Theorem 3.3.1 of Vaart and
Wellner (1996), equations (C.7) has the unique solution, and there exists the inverse
information operator I−1∞ (t, s) such that
n1/2(Ω̂− Ω0) = I−1∞ (t, s)n1/2U(Ω0) + op(1)
Take differentiation of the equation E[U(Ω0)] = 0 with respect to Ω at the true























which represents the variance of the score process n1/2U(Ω0). In addition, Andersen
et al. (2012) showed that for a differentiable functional F (Ω), by functional delta
method, n1/2{F (Ω̂)−F (Ω)} converges weakly to a zero-mean Gaussian process with
variance-covariance function Ḟ (Ω)T I−1∞ Ḟ (Ω), where Ḟ (Ω) =
∂F
∂Ω
. Applying it to the
linear functional defined in Theorem IV.2, and replacing I∞ by its consistent estimator
In, we can have the stated results.
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C.6.4 Proof of Theorem IV.3
As we defined in the proof of Theorem IV.2,
















is the asymptotic covariance matrix operator of the score for the full model. Apply












where Q = Iββ − IβHI−1HHIHβ.

























. We prove it in two steps: First,





= Q−1. Then, we prove that Iprββ
−1 p−→ Q−1.




= Q−1 is as follows:

















which is a martingale under the true model.











































































































=JβH ÎHHJHβ − 0 + JβH ÎHβ − 0 + ÎβHJHβ + Îββ
=JβH ÎHHJHβ + JβH ÎHβ + ÎβHJHβ + Îββ.




























= −ÎHβ − ÎHHJHβ
=⇒ JHβ = −Î−1HH Î
−1
Hβ
Replace the Jacobians in Iprββ with the expression above, we have
Iprββ = Îββ − ÎβH Î
−1
HH ÎHβ
p−→ Iββ − IβHI−1HHIHβ = Q.
Thus,
Iprββ
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